

Laparoscopic prediction of primary cytoreducibility of epithelial ovarian cancer

Journal: Minerva Obstetrics and Gynecology (formerly: Minerva Ginecologica)

Paper code: Minerva Obstet Gynecol-5452

Submission date: November 11, 2023

Article type: Review Article

Files:

1. Reply letter to comments on the manuscript

Version: 2

Description:

File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

2. Manuscript

Version: 4

Description: Original Manuscript

File format: application/vnd.openxmlformats-officedocument.wordprocessingml.document

1 To the Kind Attention of the Editor and Reviewers,
2 *Minerva Obstetrics and Gynecology.*
3

4
5 Thank you for giving us the opportunity to submit a revised draft of our manuscript titled
6 “Laparoscopic prediction of primary cytoreducibility of epithelial ovarian cancer” (Minerva Obstet Gynecol-
7 5452). We appreciate the time and effort that you and the reviewers have dedicated to providing your valuable
8 feedback on our manuscript. We are grateful to the reviewers for their insightful comments on our paper. We have
9 been able to incorporate changes to reflect most of the suggestions provided by the reviewers that you can find
10 highlighted within the manuscript.
11

12 Here is a point-by-point response to the reviewers’ comments and concerns.
13

14
15
16 According to the Editor's suggestions:
17

18 We thank the authors for having submitted it to this journal. Two of the referees expressed major concerns on this
19 article. We recommend to largely revision of the article before resubmitting but given this initial evaluation we
20 cannot guarantee the future acceptance of the article.
21

22
23 **We are grateful for the careful review of our manuscript, the positive comments, and the precious**
24 **suggestions to improve it.**
25

26
27 According to the Reviewer #1’s suggestions:
28

29 Thanks for the submission. It is an important subject. It would help if you summarized the included papers in a
30 table including the type of studies and main results.
31

32
33 **Thank you for these relevant suggestions. We have included a table accordingly.**
34

35
36 The language and flow need serious revision if not complete re-writing.
37

38
39 **Thank you for your valuable suggestion. A native English speaker was involved in the revision of the entire**
40 **manuscript to correct grammar and readability.**
41

42
43 Consider commenting on the quality of the papers included in the study.
44

45
46 **As suggested, we have reported in the table comments on the quality of the studies included.**
47

48
49 If re-written, kindly ensure clarity of ideas.
50

51
52 **Thanks for highlighting this important point. We decided to revise the entire manuscript to improve its**
53 **clarity.**
54
55

1
2 According to the Reviewer #2's suggestions:
3
4

5 No changes

6 **We are grateful and honored for your appreciation.**
7
8
9

10 According to the Reviewer #3's suggestions:
11
12

13 Authors attempted to bring a review of the literature regarding the role of laparoscopic evaluation and prediction
14 in advanced ovarian cancer surgery, however, the presented article reflects a chapter of a book further than a
15 review article. The paper in its current fashion does not add to the literature and does not serve as a review to the
16 readers. I would recommend rejecting the article, however, It could be considered in a special issue or as a chapter
17 of a special book on the topic.
18
19
20

21
22 **We thank the reviewer for the precise comments. The goal of our review is to summarize the data currently**
23 **available on the laparoscopic prediction of primary cytoreducibility of epithelial ovarian cancer. We think**
24 **that this review adds a broad-based view on the subject, which remains an important topic.**
25
26

27
28 Actually, the paper handles this issue comprehensively, however, long conversations and discussions should be
29 shortened and repetitions should be avoided.
30
31

32 **Thank you for this consideration. We have revised the entire manuscript to improve its clarity and**
33 **readability.**
34
35

36 For review articles there is a strong need for summarizing tables which obviously shorten the article. A statistical
37 method to summarize the discussed articles and their results in tables should be incorporated.
38
39

40 **Thank you for these relevant suggestions. We have included a table accordingly.**
41
42

43 Novel methods and scores such as the Cukurova score should be considered and referenced.
44
45

46 **Thank you for this important suggestion. We have included this novel and interesting score in the**
47 **discussions.**
48
49

50 In addition to the above comments, all spelling and grammatical errors pointed out by the
51 reviewers have been corrected. We hope that the new version of the manuscript can be considered in line with the
52 high-quality standards of the Journal. We look forward to hearing from you in due time regarding our submission
53 and to respond to any further questions and comments you may have.
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Sincerely,

On behalf of the co-authors,

Tullio Golia D'Augè, M.D.

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico
Umberto I, Rome, Italy.

Tel: +39 3408200550

Email: tullio.goliadauge@uniroma1.it

PEER REVIEW COPY
Minerva Ginecologica

1 Manuscript title: Laparoscopic prediction of primary cytoreducibility of epithelial ovarian cancer

2
3
4 Running title: Laparoscopic score of cytoreducibility in ovarian cancer

5
6
7
8 Tullio GOLIA D'AUGE' ^{1*}, Ilaria CUCCU ¹, Emanuele DE ANGELIS ¹, Violante DI DONATO ¹, Ludovico
9 MUZII ¹, Ottavia D'ORIA ^{2,3}, Vito CHIANTERA ^{4,5}, Sandro GERLI ⁶, Donatella CASERTA ⁷, Aris Raad
10 BESHARAT ^{2,7}, Antonio Simone LAGANA' ^{4,8}, Giorgio BOGANI ⁹, Alessandro FAVILLI ⁶, Andrea GIANNINI
11
12 1,2

13
14
15 ¹ Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;
16 tullio.goliadauge@uniroma1.it; andrea.giannini@uniroma1.it; ilaria.cuccu@uniroma1.it; emanuele.deangelis@uniroma1.it; violante.didonato@uniroma1.it;
17 ludovico.muzii@uniroma1.it.

18 ² Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in "Translational
19 Medicine and Oncology", Sapienza University, 00189 Rome, Italy; besharataris@gmail.com.

20 ³ Obstetrics and Gynecological Unit, Department of Woman's and Child's Health, San Camillo-Forlanini
21 Hospital, 00152 Rome, Italy; ottavia.doria@uniroma1.it.

22 ⁴ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties
23 (PROMISE), University of Palermo, 90127 Palermo, Italy; vito.chiantera@unipa.it (V.C.);
24 antoniosimone.lagana@unipa.it

25 ⁵ Unit of Gynecologic Oncology, National Cancer Institute - IRCCS - Fondazione "G. Pascale", 80131
26 Naples, Italy.

27 ⁶ Unit of Obstetrics and Gynecology, Department of Medicine and Surgery, University of Perugia, 06123
28 Perugia, Italy; sandro.gerli@unipg.it; alessandro.favilli@unipg.it.

29 ⁷ Gynecology Division, Department of Medical and Surgical Sciences and Translational Medicine,
30 Sant'Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy;
31 donatella.caserta@uniroma1.it.

32 ⁸ Unit of Obstetrics and Gynecology, "Paolo Giaccone" Hospital, 90127 Palermo, Italy.

33 ⁹ Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano,
34 Italy; bogangiorgio@gmail.com.

35 * Corresponding author: T. Golia D'Augè, Department of Maternal and Child Health and Urological
36 Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy, tullio.goliadauge@uniroma1.it
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Abstract: Ovarian cancer affects thousands of women every year and represents the female cancer with the
51 highest mortality rate. Effectively, it is a severe disease that requires a multidisciplinary approach for optimal
52 treatment. Surgery currently is the cornerstone of its treatment and numerous methods have been analyzed
53 and developed to predict the possibility of obtaining a residual tumor of 0 (RT=0). This review aims to analyze
54 the available data in the literature about minimally invasive surgical methods to predict an RT=0 in patients
55

1 with advanced epithelial ovarian carcinoma undergoing primary debulking surgery. An accurate review of the
2 literature has been performed on the available data about the surgical criteria of cytoreducibility during primary
3 debulking surgery . An accurate assessment of the extent of intra- and extra-abdominal pathology is essential
4 to guide the surgeon in the most appropriate therapeutic choice for patients with ovarian cancer and
5 multidisciplinary approaches that combine different methodologies such as radiological methods (magnetic
6 resonance imaging, positron emission tomography and computed tomography), surgical (mini-laparotomy,
7 laparoscopy) and serological (CA-125, HE4) data provide a complete picture in determining the extent of the tumor
8 and an enormous aid in personalizing the therapeutic approach.
9
10
11
12

13 Keywords: ovarian cancer; gynecologic oncology; gynecologic surgery; debulking surgery; PDS; laparoscopy.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

PEER REVIEW COPY
Minerva Ginecologica

TEXT

1. Introduction

The most frequent ovarian malignancies are epithelial tumors. Ovarian cancer affects thousands of women every year and represents the female cancer with the highest mortality rate, with an estimated 13,270 deaths in the US in 2023¹⁻³. It is most common in women over the age of 50 and its lethality is due to delayed diagnosis until advanced stages (International Federation of Gynecology and Obstetrics – FIGO stage III-IV) and to the actual lack of screening programs for an early diagnosis, compared with other gynecological tumors (in particular, breast and cervical cancer)⁴⁻⁹; moreover, epithelial ovarian carcinomas clinically manifest with poor and non-specific signs and symptoms until most advanced stages^{10,11}. The centralization of ovarian cancer care in specialized centers has been demonstrated to improve outcomes thanks to the presence of a multidisciplinary team with specialized expertise, the possibility to access clinical trials and a streamlined approach to care, facilitating efficient and coordinated treatment plans; however, recently, the survival of patients with advanced epithelial ovarian cancer (AEOC) has radically increased and their prognosis has greatly improved^{12,13}; on the one hand, the possibility of subjecting patients with increased genetic risk of developing ovarian cancer (especially with mutations of the breast cancer gene (BRCA) and homologous recombination deficiency (HRD)) to a structured screening allows a more early diagnosis; on the other hand, the introduction of antiangiogenic and poly-ADP ribose polymerase (PARP) inhibitors (PARPi) opened up new therapeutic scenarios¹⁴⁻²⁴.

Currently, surgery followed by systemic therapy is the cornerstone of the treatment of AEOC²⁵⁻³¹; however, it is essential to personalize the therapeutic approach considering patients and tumor characteristics. The goal of the surgical treatment is to reduce the residual tumor load to 0 (RT=0), meaning the absence of macroscopically visible pathology. For this purpose, the surgical approach to AEOC provides two possibilities: primary surgical treatment (primary debulking surgery, PDS) or, interval debulking surgery (IDS), performing surgery after 3 or more cycles of platinum-based chemotherapy to reduce the burden of disease. Patients may not be eligible for upfront surgery for a high load of disease and/or for the involvement of anatomical structures that cannot be excised with surgery, for the massive involvement of organs, for example, the small and the large intestine, which would require the total or almost total removal with a consequent complete loss of function, for patient's fragility, that increases the risk of intra, peri- and post-operative complications and cause an additional risk of death³²⁻⁴¹. Assessing the extent of advanced ovarian cancer requires a multidisciplinary approach involving oncologists, gynecological surgeons, radiologists and other specialists. Several methods have been analyzed and developed to predict the possibility of obtaining RT=0 (genetic, imaging, serological, surgical), but, to date, none of them can be considered the gold standard. Despite the known advantages of laparoscopic surgery in minimizing patient morbidity, in cases of uncertain operative status, an exploratory laparotomy may be strategically considered. This procedure essentially consists of a surgical dissection of the abdomen that allows a direct tissue assessment. This on-site examination facilitates the accurate determination of the extent of neoplastic pathology and the subsequent feasibility of cytoreduction surgery.

The main objective of the treatment of AEOC is to balance the risks to which the patient is exposed to achieve RT=0, the surgical effort and the achievement of an optimal cytoreduction. This narrative review aims to analyze

1 the data available in the literature about minimally invasive surgical methods to predict the optimal cytoreduction
2 of patients with AEOC undergoing PDS.
3

4 2. Materials and Methods

5
6 This is a narrative review of the available data about the criteria of cytoreducibility during PDS for the surgical
7 treatment of AEOC. The review was reported and qualitatively assessed following the SANRA, the Scale for the
8 Assessment of Narrative Review Articles ⁴². We performed the research using a narrative review method ⁴³.
9 Electronic databases PubMed (MEDLINE), Embase, Scopus, and Web of Science were searched until May 2023
10 (without date restriction) for relevant publications in the English language focusing on the use of the following
11 key search terms: ovarian cancer OR advanced epithelial ovarian cancer OR ovarian serous carcinoma AND
12 cytoreduction OR cytoreducibility AND laparoscopic OR mini-invasive technique OR mini-invasive surgery AND
13 primary debulking surgery OR PDS OR upfront surgery. The electronic search and the eligibility of studies were
14 independently assessed by two authors (T.G.D and I.C.). No restrictions on the study design were applied. The first
15 selection was based on the title, the second on the abstract, and the third on the full-text article. The bibliography
16 was also analyzed to avoid missing potentially relevant publications. The most relevant articles for this narrative
17 review were included.
18
19
20
21
22
23
24
25
26

27 3. Results

28 The role of laparoscopy in mapping advanced ovarian disease dissemination is widely recognized. This is
29 evident in authoritative sources such as the recent ESMO-ESGO consensus conference ⁴ and in the American
30 guidelines issued by the National Comprehensive Cancer Network® (NCCN®) ⁴⁴, where laparoscopy is
31 accepted as a reliable prediction tool for quantifying tumor burden and it is an optimal predictor for cytoreduction
32 planning.
33

34 The studies included are summarized in Table 1.

35 The first study to determine the role of diagnostic laparoscopy in detecting optimally cytoreducible patients
36 (reported in the study as $RT \leq 1$ cm) was performed by an Italian group in 2005 ⁴⁵. A total of 64 patients underwent
37 a diagnostic LPS, in 60.9% of cases, the abdominal disease during laparoscopy was judged to be suitable to reach
38 $RT \leq 1$ cm. In the remaining 39.1% a mini laparotomy was performed to re-evaluate the extent of the disease and
39 the concordance rate about an impossible optimal cytoreduction was 100%.
40
41
42

43 The use of scoring systems represents a method for comparing results and attributing them objectively to determine
44 the most appropriate treatment for each patient and to minimize unnecessary laparotomies.

45 Interestingly, the pathological involvement of some anatomical structures allows predicting with good accuracy (at
46 least 80%) the possibility of performing an optimal cytoreduction: ovarian masses, omental cake, peritoneal
47 carcinosis, diaphragmatic carcinosis, mesenteric retraction, bowel infiltration, stomach infiltration, liver metastases
48 and bulky lymph nodes.
49
50

51 These parameters were re-analyzed by the same group in a subsequent study ⁴⁶. A score including 6 of the listed
52 anatomical districts has been proposed to classify patients into optimally and not optimally cytoreducible. The
53 presence of ovarian masses and macroscopically pathological lymph nodes did not meet the authors' inclusion
54
55

1 criteria for inclusion in the proposed score (specificity $\geq 75\%$, positive predictive value (PPV) $\geq 50\%$, and negative
2 predictive value (NPV) $\geq 50\%$). Each parameter included in the score was assigned a value of 2 and a score was
3 assigned to each patient. This score has been defined as “predictive index score” (PIV, also known as “Fagotti
4 score”) and the cut-off ≥ 8 identified patients undergoing suboptimal surgery. Subsequently, an attempt to validate
5 this score externally was made comparing the values assigned to each variable and the overall PIV obtained in 17
6 centers specialized in gynecological oncological surgery with those of the center where the score was created⁴⁷. An
7 accuracy of more than 80% has been achieved in all centers except one.

8 A modified score was proposed in 2008 by Brun et al. including, only 4 of the 8 anatomical structures identified by
9 Fagotti et al.: diaphragmatic carcinosis, mesenteric retraction, stomach infiltration and liver metastases⁴⁸. Each of
10 the listed parameters is assigned a value of 2 if macroscopically involved by the disease and a cut-off ≤ 4 was
11 identified to consider the patient optimally cytoreducible. The authors concluded that the use of this modified score
12 allowed the detection of patients not optimally cytoreducible with sensitivity, specificity, PPV, NPV, and accuracy
13 of 35%, 100%, 100%, 43%, and 56% respectively.

14 Petrillo et al., identifying 2 variables as "absolute criteria of unresectability" (miliaric carcinomatosis on the serosa
15 of the small bowel and mesenteric retraction), proposed an alternative modified score evaluating 6 variables: (1)
16 massive peritoneal involvement and/or a miliary pattern of distribution for parietal peritoneal carcinomatosis; (2)
17 widespread infiltrating carcinomatosis, and/or confluent nodules to the most of the diaphragmatic surface; (3) tumor
18 diffusion along the omentum up to the large stomach curvature; (4) possible large/small bowel resection (excluding,
19 recto-sigmoid involvement, giving its pelvic localization and since posterior exenteration is considered a standard
20 surgical procedure in AEOC); (5) obvious neoplastic involvement of the stomach, and/or lesser omentum, and/or
21 spleen; and (6) liver surface lesions larger than 2 cm⁴⁹. After retrospectively applying this score to 234 patients
22 they demonstrated that a PIV >10 correlated with the impossibility of obtaining an optimal cytoreduction (RT < 1
23 cm) with a positive predictive value of 100%; moreover, this PIV value was associated with a high (85.7%) rate of
24 postoperative complications (Clavien/Dindo 5-6).

25 Another Italian group in 2006 demonstrated that the use of laparoscopy allowed to selection of patients eligible for
26 optimal cytoreduction based on the intrabdominal extension of disease⁵⁰. Eighty-seven patients have undergone a
27 diagnostic laparoscopy and 37 of them received neoadjuvant chemotherapy because they were not considered able
28 to tolerate major surgery (4/87 patients; 4.6%) or due to the detection of at least one of the following (30/34; 88,2%):
29 extended visceral peritoneal metastases, large involvement of upper abdomen, extended small bowel involvement,
30 multiple liver metastases, heavily bleeding tumoral tissue. Due to the use of a minimally invasive technique, the
31 authors found a low rate of major complications in both groups (only 1 case in the group of patients considered
32 fragile or with advanced disease), with RT=0 in the PDS group of 96% and in the IDS group of 86%, finding only
33 2 metastases localized at the 5 mm trocar's access. Moreover, the authors compared the data obtained with those
34 obtained before the introduction of laparoscopy as a technique to guide the therapeutic path of patients with ovarian
35 cancer; indeed, although debulking surgery was performed only in 61% of cases (obtaining any residual disease),
36 much lower than 95% in the previous period, the optimal debulking rate was increased from 46% to 96%.

37 The first multicentric randomized controlled trial (RCT) on this topic was published in 2017 by Rutten et al.⁵¹
38 including 201 patients with epithelial ovarian cancer (EOC). Thanks to the use of a minimally invasive technique
39 the rate of not optimal cytoreduction (RT >1 cm) was significantly reduced compared to the counterpart (10% vs
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1 39%, relative risk [RR], 0.25; 95% CI, 0.13 to 0.47; $p=0.001$). The parameters used to predict the non-
2 cytoreducibility during laparoscopy were principally the extensive involvement of the diaphragmatic peritoneum
3 and the presence of diffuse intrabdominal disease. No significant differences were found in overall survival (OS)
4 and progression-free survival (PFS) between the groups analyzed.

5 Although Fagotti's index is mostly used by gynecological oncology specialists in Europe for predicting surgical
6 cytoreduction, laparoscopic predictive models used for ovarian cancer analysis also include the peritoneal carcinosis
7 index, originally described by Sugarbaker⁵². The abdominal cavity is divided into nine anatomical regions, right
8 and left hypochondrium, epigastrium, right and left flank, mesogastrium, right and left iliac fossa and hypogastrium.
9 In addition, four specific subdivisions corresponding to the gastrointestinal tract are delineated: the upper jejunum,
10 the lower jejunum, the upper ileum and the lower ileum. Each area is evaluated according to a scoring system in
11 which it is assigned: 0 with no evidence of tumor; 1 when the tumor is less than 0.5 cm; 2 when the tumor is between
12 0.5 and 5 cm; 3 when the tumor exceeds 5 cm or merges with other lesions.

13 The total score varies between 0 and 39, with a 'cut-off' value between 10 and 20 to determine the adequacy of
14 surgical cytoreduction^{53,54}.

15 Recently, Di Donna et al. suggested that the laparoscopic score assessment had high accuracy for optimal
16 cytoreduction in AOEC patients undergoing PDS or IDS⁵⁵. In particular, in patients undergoing PDS, the
17 laparoscopic Predictive Index (PI) and the laparotomic Peritoneal Cancer Index (PCI) had the best accuracies for
18 complete cytoreduction (R0); in women undergoing IDS, the laparotomic PI (Area under the ROC Curve (AUC) =
19 0.75) and the laparoscopic PCI (AUC= 0.87) were associated with the best accuracy in RT=0 prediction.

20 A comparative analysis of the scores developed by Sugarbaker and Fagotti, aimed at assessing their efficacy in
21 predicting complete debulking, performed by either laparoscopic or laparotomic approaches, was conducted within
22 a non-randomized retrospective study conducted by Climent et al⁵⁶. This study involved a cohort of 34 patients
23 who met the eligibility criteria, 85.3% of whom had peritoneal carcinomatosis of ovarian origin. The analysis
24 revealed that the peritoneal carcinomatosis indicator proved to be the strongest predictor, regardless of the surgical
25 approach employed (laparoscopic or laparotomic).

26 The results of the analysis indicated that when the Peritoneal Carcinomatosis Score (PCI) ≥ 20 , the test achieved a
27 sensitivity and specificity of 43% and 88%, respectively. The overall accuracy of the index was 79%, with positive
28 and negative prediction values of 50% and 86%, respectively.

29 The R3 and R4 models are alternative predictive models to assess suitability for surgical cytoreduction for advanced
30 ovarian cancer⁵³. Overall, 110 patients with advanced ovarian cancer were included. The data extracted from the
31 cohort were used to develop two separate predictive models. Clinical, pathological and surgical data were collected
32 and submitted for analysis to determine the Peritoneal Tumor Load Index (PCI) and the Lesion Size Relative Score.
33 The R3 model score is a measure of the severity of the bowel obstruction, based on preoperative imaging, surgical
34 findings, and clinical symptoms. The R4 model score adds operative PCI to the R3 model score, which may provide
35 a more accurate assessment of the severity of the obstruction and the risk of complications. Lesions were evaluated
36 in 13 different anatomical regions within the abdomen and pelvis, with subsequent transposition of the respective
37 dimensions into a numerical scale ranging from 0 to 3, contributing to an overall maximum score of 39. If more
38 than one lesion was found within a single region, the largest was included in the score calculation. Complete
39 cytoreduction was categorized as the macroscopic absence of tumor residual; optimal cytoreduction was defined as

1 the presence of a residual tumor with a diameter of less than 1 centimeter; suboptimal cytoreduction was established
2 in the presence of a residual tumor greater than 1 centimeter. Each model presented a tripartite stratification of risk
3 score and proved capable of predicting both suboptimal or complete and optimal surgical cytoreduction eligibility,
4 with a sensitivity of 83% (R4 model) and 69% (R3 model), respectively. A PCI > 20 was found to be a significant
5 risk factor for surgical unresectability.
6
7

8 A subsequent study conducted by Lluca A et al.⁵⁷ analyzed the prognostic performance of these models, comparing
9 them with the Fagotti model, to predict suboptimal surgical cytoreduction in a cohort of 103 patients with advanced
10 ovarian cancer. The results showed that the three models were able to satisfactorily predict suboptimal surgical
11 cytoreduction for advanced ovarian cancer, although they were most reliable in predicting complete surgical
12 cytoreduction. Model R4 demonstrated superior efficacy compared to the others by the inclusion of laparotomic
13 assessment of the peritoneal carcinomatosis index.
14
15
16

17 4. Discussion

18
19 After the introduction into clinical practice of maintenance therapies (in particular Vascular endothelial growth
20 factor (VEGF) inhibitors and PARPi(s)), ovarian epithelial carcinomas can be considered a chronic disease^{4,17,19-}
21^{21,58}. Therefore, although relapse rates change according to the type of maintenance therapy that each patient can
22 benefit from, according to the molecular status (mutations in BRCA and HRD genes) and the County's
23 reimbursement policy, the course of the disease is predominantly influenced by the radicality of the surgical
24 treatment (primary or after neoadjuvant chemotherapy)^{19,23,59}.
25
26

27 At present, obtaining an absent residue of disease is the main goal of the surgical approach; indeed, an RT=0 is a
28 breakpoint to direct each patient toward a first-instance surgery or its reevaluation after 3 or more cycles of platinum-
29 based chemotherapy⁶⁰⁻⁶³.
30
31

32 The ability to perform optimal cytoreduction is a crucial aspect of cancer surgery. It is primarily tied to the extent
33 of the disease and its accurate assessment is essential. However, it should be noted that the main challenge in this
34 context is the validation of predictive models. For this reason, several authors have proposed surgical and non-
35 surgical models aimed at assessing the feasibility and success of optimal cytoreduction of advanced ovarian cancer
36^{52,53,64}.
37
38

39 The complexity of laparoscopy in advanced ovarian carcinoma is intrinsically related to its limited ability to
40 exhaustively explore deep abdominal cavities. This inherent restriction results in a limitation in anatomical imaging,
41 which may be a major determinant of tumor surgical unresectability. Specifically, anatomical regions such as the
42 hepatic pedicle, the retrohepatic region and the retroperitoneal space may be under-represented or even completely
43 inaccessible by the laparoscopic approach and there is a need for advanced and specific imaging methodologies to
44 conduct an accurate analysis of these anatomical regions. This approach is a crucial tool to minimize the adoption
45 of unnecessary laparotomies⁶⁵.
46
47

48 Several authors have reported promising results in predicting the suitability for optimal cytoreduction using
49 radiological imaging alone; however, it is imperative to emphasize that these results have not yet been universally
50 validated⁶⁶.
51
52

53 Axtell et al. analyzing the data of 65 patients with AEOC subjected to PDS have identified 2 predictors of suboptimal
54 cytotoxicity evaluable with CT scan: the presence of diaphragmatic disease and the involvement of the intestinal
55

mesentery (risk ratio 5.69 e 6.07, respectively) ⁶⁷. However, the authors suggest using such predictors critically in the decision between upfront surgery and IDS.

Other authors have hypothesized a role of the massive ascitic effusion in predicting an optimal cytoreduction, however, without **demonstrating** any statistically significant correlation ^{62,68,69}.

In this same line of research, Gerstein et al. conducted a study **including of 115 patients** to develop a nomogram based on predictive parameters that may facilitate the prediction of suboptimal cytoreduction ⁷⁰. The analysis identified that preoperative platelet count (p=0.1990), diffuse peritoneal thickening (p=0.0074), and the presence of ascites in at least two-thirds of the CT scan sections were predictive of residual disease greater than 1 centimeter after cytoreduction. This nomogram accurately predicted the surgical outcome in 74% **cases**. However, further external validation studies are needed to confirm the reliability and applicability of this tool in clinical practice.

Moreover, gene expression analysis emerges as a constantly developing field of research. This discipline focuses on understanding and utilizing genetic information to prescribe the most appropriate therapeutic strategy for patients with malignancies. This approach **assumes** that the genetic profile of tumors may condition the response to specific treatments **and** assumes a key role in determining whether surgical action is warranted, as well as outlining the appropriate timing and extent of surgery. This is achieved through the application of sophisticated methodologies for analyzing the genetic profile of tumors, such as transcriptomic analysis of messenger RNA and genomic investigation of genetic mutations. In a study conducted by Reem Abdallah et al. an initial analysis was carried out involving over 12,000 genes. This investigation revealed that 58 of these genes had a predictive accuracy for cytoreduction of 69% (p = 0.005). In a second in-depth analysis, 220 genes emerged as predictors of cytoreduction accuracy in 74% of cases. Unfortunately, these patterns were not uniformly confirmed in independently conducted gene expression experiments ⁷¹.

Furthermore, several tumor markers have been proposed to predict the cytoreductivity of malignant ovarian tumors: Angioli et al. proposed a value of the serum tumor marker Human epididymis protein 4 (HE4) ≤ 262 pmol/L as predictive of RT ≤ 1 cm; studies on the use of pre-operative cancer antigen 125 (CA125) values are conflicting about the possibility of its use as a predictor of surgical radicality ⁷². **The** association of different parameters has been considered to propose an accurate score without having reached this goal until now ⁷³⁻⁷⁵. Interestingly, further therapeutic targets are under evaluation ⁷⁶⁻⁸⁰. Prediction of optimal cytoreduction through gene and marker expression is an evolving field that could have a significant impact on personalizing treatments for cancer patients.

Many radiomic nomograms based on MRI image analysis were developed, demonstrating a remarkable accuracy, sensitivity, and specificity of 85.0%, 87.0%, and 80.0%, respectively, **suggesting** that MRI-based radiomic nomograms may be a reliable tool to guide therapeutic decisions and improve the accuracy in predicting therapeutic outcomes in patients with advanced ovarian cancer ^{81,82}.

Finally, the Cukurova score was recently proposed for stratifying patients who may benefit from primary debulking surgery ⁸³. This score integrates the performance status of each patient with laparoscopic and video-assisted thoracic surgery parameters, clinical parameters and anticipated surgical procedures with imaging. The authors showed that a cut-off ≤ 12 can predict in over 96% of cases a complete cytoreduction rate at primary debulking surgery for AEOC, moreover, a score >12 correlated with post-operative complication rates and higher mortality ⁸³.

In conclusion, the assessment of the extent of intra- and extra-abdominal pathology is of paramount importance in the management of patients with AEOC. By using a multidisciplinary approach that combines radiological methods

1 such as MRI, PET and computed tomography, surgical techniques such as mini-laparotomy and laparoscopy, and
2 genetic and serological markers such as CA-125 and HE4, it is possible to customize the therapeutic approach for
3 these patients. The use of advanced imaging methods such as MRI and PET allows for a more detailed assessment
4 of the extent of the disease, identifying possible metastases and involvement of surrounding tissues. Mini-LPTM
5 and LPS surgical techniques offer less invasive options for the removal of ovarian tumors while reducing recovery
6 time and potential side effects. Genetic markers such as CA-125 and HE4 can provide further information on the
7 presence and severity of the tumor. In addition, these markers can be used to monitor response to treatment and
8 disease recurrence. The multidisciplinary approach described is essential to improve the outcomes of patients with
9 AEOC, allowing the most appropriate treatment to be adopted according to the severity and extent of the disease.
10 This holistic approach aims to improve the quality of care and provide personalized treatment to people facing the
11 challenges of advanced epithelial ovarian cancer.
12
13
14
15

16 REFERENCES

- 17
18
19
20
21 1. Cancer of the Ovary - Cancer Stat Facts Available online: <https://seer.cancer.gov/statfacts/html/ovary.html>
22 (accessed on 23 October 2023).
23
- 24
25 2. Ovarian Cancer Statistics | How Common Is Ovarian Cancer Available online:
26 <https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html> (accessed on 23 October 2023).
27
- 28
29 3. Pecorino B, Laganà, A.S, Chiantera V, Ferrara M, Di Stefano A.B, Di Donna M.C, et al. Progression Free
30 Survival, Overall Survival, and Relapse Rate in Endometrioid Ovarian Cancer and Synchronous Endometrial-
31 Ovarian Endometrioid Cancer (SEO-EC): Results from a Large Retrospective Analysis. *Medicina (Kaunas)* 2022,
32 58, 1706
33
- 34
35 4. Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage W.G., McNeish I, et al. ESMO-ESGO
36 Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and
37 Advanced Stages, Borderline Tumours and Recurrent Disease†. *Ann Oncol* 2019, 30, 672–705
38
- 39
40 5. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann, J, et al. ESMO-ESGO-
41 ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-Up. *Ann Oncol* 2016,
42 27, 16–41
43
- 44
45 6. Giannini A, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, et al. Outcomes of High-
46 Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization. *Vaccines (Basel)*
47 2023, 11, 698
48
- 49
50 7. Coleman C. Early Detection and Screening for Breast Cancer. *Semin Oncol Nurs* 2017, 33, 141–155
51
- 52
53 8. Bevers T.B, Helvie M, Bonaccio E, Calhoun K.E, Daly M.B, Farrar W.B, et al. Breast Cancer Screening
54 and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2018,
55 16, 1362–1389

- 1 9. Giannini A, Bogani G, Vizza E, Chiantera V, Laganà A.S, Muzii L, et al. Advances on Prevention and
2 Screening of Gynecologic Tumors: Are We Stepping Forward? *Healthcare (Basel)* 2022, 10, 1605
- 3
- 4 10. Raspagliesi F, Bogani G, Benedetti S, Grassi S, Ferla S, Buratti S. Detection of Ovarian Cancer through
5 Exhaled Breath by Electronic Nose: A Prospective Study. *Cancers (Basel)*. 2020;12(9):2408.
- 6
- 7 11. Fischetti M, Di Donato V, Palaia I, Perniola G, Tomao F, Perrone C, et al. Advances in Small Molecule
8 Maintenance Therapies for High-Grade Serous Ovarian Cancer. *Expert Opin Pharmacother* 2023, 24, 65–72
- 9
- 10 12. Bogani G, Ditto A, Pinelli C, Lopez S, Chiappa V, Raspagliesi F. Ten-year follow-up study of long-term
11 outcomes after conservative surgery for early-stage ovarian cancer. *Int J Gynaecol Obstet*. 2020;150(2):169-176
- 12
- 13 13. Margioulas-Siarkou C, Petousis S, Papanikolaou A, Gullo G, Margioulas-Siarkou G, Laganà A.S, et al.
14 Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer - State of the Art. *Prz Menopauzalny* 2022, 21,
15 272–275
- 16
- 17 14. Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian Cancer Prevention and Screening. *Obstet Gynecol*
18 2018, 131, 909–927,
- 19
- 20
- 21 15. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso M.J, Gilbert F, et al. ESMO Guidelines
22 Committee Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer
23 Syndromes: ESMO Clinical Practice Guidelines for Cancer Prevention and Screening. *Ann Oncol* 2016, 27, v103–
24 v110
- 25
- 26
- 27 16. LeVasseur N, Chia S. Cancer Screening and Prevention in BRCA Mutation Carriers: A Missed
28 Opportunity? *Br J Cancer* 2019, 121, 1–2
- 29
- 30
- 31 17. Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, et al. Bevacizumab in Ovarian
32 Cancer: State of the Art and Unanswered Questions. *Chemotherapy* 2017, 62, 111–120
- 33
- 34
- 35 18. Tomao F, Marchetti C, Romito A, Di Pinto A, Di Donato V, Capri O, et al. Overcoming Platinum
36 Resistance in Ovarian Cancer Treatment: From Clinical Practice to Emerging Chemical Therapies. *Expert Opin*
37 *Pharmacother* 2017, 18, 1443–1455,
- 38
- 39
- 40 19. Moore K, Colombo N, Scambia G, Kim B.-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in
41 Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2018, 379, 2495–2505
- 42
- 43
- 44 20. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus
45 Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med* 2019, 381, 2416–2428
- 46
- 47
- 48 21. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza M.R, et al. Niraparib
49 in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019, 381, 2391–2402
- 50
- 51
- 52 22. Monk B.J, Coleman R.L, Fujiwara K, Wilson M.K, Oza A.M, Oaknin A, et al. ATHENA (GOG-
53 3020/ENGOT-Ov45): A Randomized, Phase III Trial to Evaluate Rucaparib as Monotherapy (ATHENA-MONO)
- 54
- 55

- 1 and Rucaparib in Combination with Nivolumab (ATHENA-COMBO) as Maintenance Treatment Following
2 Frontline Platinum-Based Chemotherapy in Ovarian Cancer. *Int J Gynecol Cancer* 2021, 31, 1589–1594,
3
4
5 23. Casarin J, Bogani G, Multinu F, Mariani, A, Abu-Rustum N.R, Ghezzi F, et al. Paradigm Shifts in
6 Gynecologic Oncology. *Int J Gynecol Cancer* 2021, 31, 1617
7
8
9 24. Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, et al. In-House Testing for
10 Homologous Recombination Repair Deficiency (HRD) Testing in Ovarian Carcinoma: A Feasibility Study
11 Comparing AmoyDx HRD Focus Panel with Myriad MyChoiceCDx Assay. *Pathologica* 2022, 114, 288–294
12
13
14 25. Fagotti A, Ferrandina M.G, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized Trial of
15 Primary Debulking Surgery versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer
16 (SCORPION-NCT01461850). *Int J Gynecol Cancer* 2020, 30, 1657–1664
17
18
19 26. Kotsopoulos I.C, Graham R, Mould T. SCORPION Study: Is It Time to Call Primary Debulking Surgery
20 Superior? *Int J Gynecol Cancer* 2021, 31, 310
21
22
23 27. Vergote I, Amant F, Kristensen G, Ehlen T, Reed N.S, Casado A. Primary Surgery or Neoadjuvant
24 Chemotherapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer. *Eur J Cancer* 2011, 47 Suppl
25 3, S88-92
26
27
28 28. Benedetti Panici P, Giannini A, Fischetti M, Lecce F, Di Donato V. Lymphadenectomy in Ovarian Cancer:
29 Is It Still Justified? *Curr Oncol Rep* 2020, 22, 22
30
31
32 29. Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, et al. Trends in Mortality After
33 Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized
34 Clinical Trials and Observational Studies. *Ann Surg Oncol* 2017, 24, 1688–1697
35
36
37 30. Peiretti M, Zanagnolo V, Aletti G.D, Bocciolone L, Colombo N, Landoni F, et al. Role of Maximal Primary
38 Cytoreductive Surgery in Patients with Advanced Epithelial Ovarian and Tubal Cancer: Surgical and Oncological
39 Outcomes. Single Institution Experience. *Gynecol Oncol* 2010, 119, 259–264
40
41
42 31. Giannini A, D’Oria O, Bogani G, Di Donato V, Vizza E, Chiantera V, et al. Hysterectomy: Let’s Step Up
43 the Ladder of Evidence to Look Over the Horizon. *J Clin Med* 2022, 11, 6940
44
45
46 32. Aletti G.D, Gostout B.S, Podratz K.C, Cliby W.A. Ovarian Cancer Surgical Resectability: Relative Impact
47 of Disease, Patient Status, and Surgeon. *Gynecol Oncol* 2006, 100, 33–37
48
49
50 33. Aletti G.D, Dowdy S.C, Podratz K.C, Cliby W.A. Analysis of Factors Impacting Operability in Stage IV
51 Ovarian Cancer: Rationale Use of a Triage System. *Gynecol Oncol* 2007, 105, 84–89
52
53
54
55

- 1 34. Di Donato V, Di Pinto A, Giannini A, Caruso G, D’Oria O, Tomao F, et al. Modified Fragility Index and
2 Surgical Complexity Score Are Able to Predict Postoperative Morbidity and Mortality after Cytoreductive Surgery
3 for Advanced Ovarian Cancer. *Gynecol Oncol* 2021, 161, 4–10
4
5
6 35. Thrall M.M, Goff B.A, Symons R.G, Flum D.R, Gray H.J. Thirty-Day Mortality after Primary
7 Cytoreductive Surgery for Advanced Ovarian Cancer in the Elderly. *Obstet Gynecol* 2011, 118, 537–547
8
9
10 36. Armstrong D.K, Alvarez R.D, Bakkum-Gamez J.N, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian
11 Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021, 19, 191–
12 226
13
14
15 37. Bogani G, Borghi C, Ditto A, Signorelli M, Martinelli F, Chiappa V, et al. Impact of Surgical Route in
16 Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging. *J Minim Invasive Gynecol* 2017,
17 24, 739–746
18
19
20 38. Davidson B.A, Broadwater G, Crim A, Boccacio R, Bixel K, Backes F, et al. Surgical Complexity Score
21 and Role of Laparoscopy in Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
22 *Gynecol Oncol* 2019, 152, 554–559
23
24
25 39. Di Donato V, Giannini A, D’Oria O, Schiavi M.C, Di Pinto A, Fischetti M, et al. Hepatobiliary Disease
26 Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction. *Ann*
27 *Surg Oncol* 2021, 28, 222–230
28
29
30 40. Di Donato V, D’Oria O, Giannini A, Bogani G, Fischetti M, Santangelo G, et al. Age-Adjusted Charlson
31 Comorbidity Index Predicts Survival in Endometrial Cancer Patients. *Gynecol Obstet Invest* 2022, 87, 191–199
32
33
34 41. D’Oria O, Golia D’Auge T, Baiocco E, Vincenzoni C, Mancini E, Bruno V, et al. The Role of Preoperative
35 Frailty Assessment in Patients Affected by Gynecological Cancer: A Narrative Review. *Ital J Gynaecol Obstet* 2022,
36 34, 76
37
38
39 42. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review
40 articles. *Res Integr Peer Rev.* 2019;4:5.
41
42
43 43. Gregory A.T, Denniss A.R. An Introduction to Writing Narrative and Systematic Reviews - Tasks, Tips
44 and Traps for Aspiring Authors. *Heart Lung Circ.* 2018;27(7):893-898.
45
46
47 44. Uterine Neoplasms Version 1.2024. Available online:
48 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. (accessed on 23 October 2023).
49
50
51 45. Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa A.C,et al. Role of Laparoscopy to Assess the
52 Chance of Optimal Cytoreductive Surgery in Advanced Ovarian Cancer: A Pilot Study. *Gynecol Oncol* 2005, 96,
53 729–735
54
55

- 1 46. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A Laparoscopy-Based Score to
2 Predict Surgical Outcome in Patients with Advanced Ovarian Carcinoma: A Pilot Study. *Ann Surg Oncol* 2006, 13,
3 1156–1161
4
5
6 47. Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato V.D, et al. A Multicentric Trial (Olympia-
7 MITO 13) on the Accuracy of Laparoscopy to Assess Peritoneal Spread in Ovarian Cancer. *Am J Obstet Gynecol*
8 2013, 209, 462.e1-462.e11
9
10
11 48. Brun J.-L, Rouzier R, Uzan S, Daraï E. External Validation of a Laparoscopic-Based Score to Evaluate
12 Resectability of Advanced Ovarian Cancers: Clues for a Simplified Score. *Gynecol Oncol* 2008, 110, 354–359
13
14
15 49. Petrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V, et al. Definition of a Dynamic
16 Laparoscopic Model for the Prediction of Incomplete Cytoreduction in Advanced Epithelial Ovarian Cancer: Proof
17 of a Concept. *Gynecol Oncol* 2015, 139, 5–9
18
19
20 50. Angioli R, Palaia I, Zullo M.A, Muzii L, Mancini N, Calcagno M, et al. Diagnostic Open Laparoscopy in the
21 Management of Advanced Ovarian Cancer. *Gynecol Oncol* 2006, 100, 455–461
22
23
24 51. Rutten M.J, Gaarenstroom K.N, Van Gorp T, van Meurs H.S, Arts H.J, Bossuyt P.M, et al. Laparoscopy to
25 Predict the Result of Primary Cytoreductive Surgery in Advanced Ovarian Cancer Patients (LapOvCa-Trial): A
26 Multicentre Randomized Controlled Study. *BMC Cancer* 2012, 12, 31
27
28
29 52. Jacquet P, Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with
30 peritoneal carcinomatosis. *Cancer Treat Res.* 1996;82:359-74.
31
32
33 53. Lluca A, Serra A, Delgado K, Maiocchi K, Jativa R, Gomez L, et al. A radiologic-laparoscopic model to
34 predict suboptimal (or complete and optimal) debulking surgery in advanced ovarian cancer: a pilot study. *Int J*
35 *Womens Health.* 2019;11:333-342.
36
37
38 54. Lluca A, Escrig, J, MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology
39 Surgery). Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. *Eur J Surg Oncol.*
40 2018;44(1):163-169.
41
42
43 55. Di Donna M.C, Cucinella G, Zaccaria G, Lo Re G, Crapanzano A, Salerno S, et al. Concordance of
44 Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced
45 Ovarian Cancer. *Cancers (Basel)* 2023, 15, 500
46
47
48 56. Climent M. T, Serra A, Gilabert-Estellés J, Gilabert-Aguilar J, Lluca, A. Comparison of Peritoneal
49 Carcinomatosis Scoring Methods in Predicting Resectability and Prognosis in Gynecologic Malignancies. *J Clin*
50 *Med.* 2021;10(12):2553.
51
52
53
54
55

- 1 57. Lluca A, Climent M.T, Escrig J, Carrasco P, Serra A, MUAPOS working group (Multidisciplinary Unit
2 of Abdominal Pelvic Oncology Surgery). Validation of three predictive models for suboptimal cytoreductive
3 surgery in advanced ovarian cancer. *Sci Rep.* 2021;11(1):8111.
4
- 5
6 58. Burger R.A, Brady M.F, Bookman M.A, Fleming G.F, Monk B.J, Huang H, et al. Incorporation of
7 Bevacizumab in the Primary Treatment of Ovarian Cancer. *N Engl J Med* 2011, 365, 2473–2483,
8
9
- 10 59. Feys T. BROADENED REIMBURSEMENT CRITERIA FOR THE PARP INHIBITOR OLAPARIB
11 Available online: [https://www.bjmo.be/broadened-reimbursement-criteria-for-the-parp-inhibitor-olaparib-in-](https://www.bjmo.be/broadened-reimbursement-criteria-for-the-parp-inhibitor-olaparib-in-prostate-breast-and-pancreatic-cancers/)
12 [prostate-breast-and-pancreatic-cancers/](https://www.bjmo.be/broadened-reimbursement-criteria-for-the-parp-inhibitor-olaparib-in-prostate-breast-and-pancreatic-cancers/) (accessed on 23 October 2023).
13
14
- 15 60. Chiofalo B, Bruni S, Certelli C, Sperduti I, Baiocco E, Vizza E. Primary Debulking Surgery vs. Interval
16 Debulking Surgery for Advanced Ovarian Cancer: Review of the Literature and Meta-Analysis. *Minerva Med* 2019,
17 110, 330–340
18
19
- 20 61. Sørensen S.M, Høgdall C, Mosgaard B.J, Dalgaard M.I.R, Jensen M.P, Fuglsang K, et al. Residual Tumor
21 and Primary Debulking Surgery vs Interval Debulking Surgery in Stage IV Epithelial Ovarian Cancer. *Acta Obstet*
22 *Gynecol Scand* 2022, 101, 334–343
23
24
- 25 62. Ghirardi V, Moruzzi M.C, Bizzarri N, Vargiu V, D'Indinosante M, Garganese G, et al. Minimal Residual
26 Disease at Primary Debulking Surgery versus Complete Tumor Resection at Interval Debulking Surgery in
27 Advanced Epithelial Ovarian Cancer: A Survival Analysis. *Gynecol Oncol* 2020, 157, 209–213
28
29
- 30 63. Bryant A, Hiu S, Kunonga P.T, Gajjar K, Craig D, Vale L, et al. Impact of Residual Disease as a Prognostic
31 Factor for Survival in Women with Advanced Epithelial Ovarian Cancer after Primary Surgery. *Cochrane Database*
32 *Syst Rev* 2022, 9, CD015048,
33
34
- 35 64. Suidan R.S, Ramirez P. T, Sarasohn D. M, Teitcher J. B, Iyer R. B, Zhou Q, et al. A multicenter assessment
36 of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary
37 debulking for advanced epithelial ovarian cancer. *Gynecol Oncol.* 2017;145(1):27-31.
38
39
- 40 65. Defieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction
41 in advanced stages of epithelial ovarian cancer. *Int J Gynecol Cancer.* 2006;16 Suppl 1:35-40.
42
43
- 44 66. Feng Z, Wen H, Jiang Z, Liu S, Ju X, Chen X, et al. A triage strategy in advanced ovarian cancer
45 management based on multiple predictive models for R0 resection: a prospective cohort study. *J Gynecol Oncol.*
46 2018;29(5):e65.
47
48
- 49 67. Axtell A.E, Lee M.H, Bristow R.E, Dowdy S.C, Cliby W.A, Raman S, et al. Multi-Institutional Reciprocal
50 Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients with
51 Advanced Ovarian Cancer. *J Clin Oncol* 2007, 25, 384–389,
52
53
54
55

- 1 68. Vergote I, de Wever, I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam, P. Interval Debulking Surgery:
2 An Alternative for Primary Surgical Debulking? *Semin Surg Oncol* 2000, 19, 49–53
3
- 4 69. Barlow T.S, Przybylski M, Schilder J.M, Moore D.H, Look K.Y. The Utility of Presurgical CA125 to
5 Predict Optimal Tumor Cytoreduction of Epithelial Ovarian Cancer. *Int J Gynecol Cancer* 2006, 16, 496–500
6
7
- 8 70. Gerestein C. G, Eijkemans M. J, Bakker J, Elgersma O. E, van der Burg M. E, Kooi G, et al. Nomogram
9 for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. *Anticancer Res.*
10 2011;31(11):4043-9.
11
12
- 13 71. Abdallah R, Chon H. S, Bou Zgheib N, Marchion D. C, Wenham R. M, Lancaster J. M, et al. Prediction of
14 Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data. *Int J Gynecol Cancer.*
15 2015;25(6):1000-9.
16
17
- 18 72. Angioli R, Plotti, F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the Preoperative HE4 Level
19 Predict Optimal Cytoreduction in Patients with Advanced Ovarian Carcinoma? *Gynecol Oncol* 2013, 128, 579–583
20
21
- 22 73. El-Agwany A.S. Laparoscopy and Computed Tomography Imaging in Advanced Ovarian Tumors: A
23 Roadmap for Prediction of Optimal Cytoreductive Surgery. *Gynecol Minim Invasive Ther* 2018, 7, 66–69
24
25
- 26 74. Abdalla Ahmed S, Abou-Taleb H, Ali N, M Badary D. Accuracy of Radiologic- Laparoscopic Peritoneal
27 Carcinomatosis Categorization in the Prediction of Surgical Outcome. *Br J Radiol* 2019, 92, 20190163
28
29
- 30 75. De Jong D, Eijkemans M.J, Lie Fong S, Gerestein C.G, Kooi G.S, Baalbergen A, et al. Preoperative
31 Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma. *Oncology* 2007, 72, 293–301
32
- 33 76. Gilbert L, Oaknin, A, Matulonis U.A, Mantia-Smaldone G.M, Lim P.C, Castro C.M., et al. Safety and
34 efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in
35 combination with bevacizumab in patients with platinum-resistant ovarian cancer. *Gynecol Oncol.* 2023;170:241-
36 247.
37
38
- 39 77. Indinj A, Nigro O, Lengyel C.G, Ghidini M, Petrillo A, Lopez S, et al. Immune-Checkpoint Inhibitors in
40 Platinum-Resistant Ovarian Cancer. *Cancers (Basel).* 2021;13(7):1663.
41
42
- 43 78. Bogani G, Lopez S, Mantiero M, Ducceschi M, Bosio S, Ruisi S, et al. Immunotherapy for platinum-
44 resistant ovarian cancer. *Gynecol Oncol.* 2020;158(2):484-488.
45
46
- 47 79. Bogani G, Monk B.J, Coleman R.L, Vergote I, Oakin A, Ray-Coquard I, et al. Selinexor in patients with
48 advanced and recurrent endometrial cancer. *Curr Probl Cancer.* 2023:100963. doi:
49 10.1016/j.currprobcancer.2023.100963.
50
51
- 52 80. Bogani G, Coleman R.L, Vergote I, Raspagliesi F, Lorusso D, Monk B.J. Tisotumab vedotin in recurrent
53 or metastatic cervical cancer. *Curr Probl Cancer.* 2023;47(3):100952.
54
55

- 1 81. Mao M. M, Li H. M, Shi J, Qiu Q. S, Feng F. [Prediction of platinum-based chemotherapy sensitivity for
2 epithelial ovarian cancer by multi-sequence MRI-based radiomic nomogram]. *Zhonghua Yi Xue Za Zhi.*
3 2022;102(3):201-208. Chinese.
4
5
6 82. Wang T, Wang H, Wang Y, Liu X, Ling L, Zhang G, et al. MR-based radiomics-clinical nomogram in
7 epithelial ovarian tumor prognosis prediction: tumor body texture analysis across various acquisition protocols. *J*
8 *Ovarian Res.* 2022;15(1):6.
9
10
11 83. Khatib G, Seyfettinoglu S, Kose S, Kucukgoz Gulec U, Avcı A, Güzel AB, et al. The Cukurova score in
12 the prediction of primary cytoreduction in ovarian cancer. *Int J Gynecol Cancer.* 2023:ijgc-2023-004736.
13
14

15 Conflicts of interest

16 The authors declare no conflict of interest.
17
18

19 Funding

20 This research received no external funding.
21
22

23 Authors' contributions

24
25 Conceptualization and writing—review and editing, T.G.D.; methodology and software, I.C.; E.D.A.; validation,
26 V.D.D., L.M. and O.D.; formal analysis, V.C.; investigation, S.G.; resources, A.R.B.; data curation, A.S.L.;
27 writing—original draft preparation, A.F.; L.M.; visualization, G.B.; supervision, A.G. and D.C.; project
28 administration, V.D.D. All authors have read and agreed to the published version of the manuscript.
29
30
31

32 Table legend

33 Table 1. Summary of studies included.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Table 1. Summary of studies included.

Author	Year	Type	N pat	Score	Objective	Results	Conclusion
Fagotti [45]	2005	Prospective	64	Fagotti score	Optimal cytoreduction	Accuracy rate of laparoscopy was 90%.	Laparoscopy can be considered impossible to standard longitudinal laparotomy in identifying not optimally resectable
Fagotti [46]	2006	Prospective	64	Fagotti score	Optimal cytoreductive surgery	A predictive index score ≥ 8 identified patients undergoing suboptimal surgery with a specificity of 100%	The reliability of laparoscopy in assessing the chance of optimal cytoreduction can be improved by using a simple scoring system.
Fagotti [47]	2013	Prospective	120	Fagotti score	Optimal cytoreduction	All but 1 satellite center, reached an accuracy rate of 80% or greater for both single parameters and overall score	LPS allows an accurate and reliable assessment of intraperitoneal diffusion of disease
Jean-Luc Brun [48]	2008	Retrospective	55	Modified score of Fagotti score	Optimal cytoreductive surgery	A modified score of ≥ 4 was associated with suboptimal cytoreduction.	This simplified laparoscopy-based score was at least as accurate as the Fagotti score to predict resectability
M Petrillo [49]	2015	Prospective	234	Laparoscopy-based predictive index model	Incomplete cytoreduction	At a Laparoscopy-based predictive index model ≥ 10 the chance of achieving complete Primary debulking surgery was 0, and the risk of unnecessary laparotomy was 33.2%.	Staging laparoscopy is confirmed as an accurate tool in the prediction of complete Primary debulking surgery
Roberto Angioli [50]	2006	Prospective	87	Diagnostic open laparoscopy	Optimal primary cytoreductive surgery	Diagnostic laparoscopy allows to select patients for optimal primary cytoreductive surgery.	Diagnostic open laparoscopy could be considered a valid diagnostic tool in evaluating the extent of disease
Marianne J Rutten [51]	2012	Randomized	200	Additional diagnostic laparoscopy	Suboptimal cytoreductive surgery	Patients who have disease considered to be resectable to less than one centimeter	Laparoscopy before starting treatment for ovarian cancer can be an additional diagnostic tool to predict the outcome of primary debulking surgery

1						should undergo primary debulking surgery to improve prognosis.		
2								
3								
4								
5								
6								
7								
8	Antoni Lluca [53]	2019	Prospective, analyzed retrospectively	110	R4 model (included operative PCI), R3 model	Suboptimal and optimal cytoreductive surgery and	Sensitivity of 83% (R4 model) Sensitivity of 69% (R3 model)	PCI>20 was a major risk factor for unresectability
9								
10								
11								
12	Antoni Lluca [54]	2018	Retrospective	80	PCI score	evaluate the prognostic value of PCI	PCI was significantly associated with suboptimal surgery	PCI may provide important information for surgical planning
13								
14								
15								
16								
17	Mariano Catello Di Donna [55]	2023	Retrospective	100 (69 underwent PD S 31 underwent NACT and IDS)	Predictive Index score Peritoneal Cancer Index score	Complete cytoreduction	In patients undergoing PDS, the laparoscopic PI and the laparotomic PCI had the best accuracies for complete cytoreduction (R0) In the IDS group, the laparotomic PI were associated with the best accuracy in R0 prediction	Laparoscopic score assessment had high accuracy for optimal cytoreduction in patients undergoing PDS or IDS.
18								
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								
31								
32								
33								
34	María Teresa Climent [56]	2021	Retrospective	34	Fagotti's index Sugarbaker's peritoneal cancer index	Optimal and suboptimal surgery	The rate of complete cytoreductive surgery was 79.4% The highest sensitivity was obtained with a PCI > 20.	The best diagnostic method to classify patients with peritoneal cancer is the PCI
35								
36								
37								
38								
39								
40								
41								
42								
43	Antoni Lluca [57]	2021	Prospective, analyzed retrospectively	103	Fagotti R3 models R4 models	Suboptimal cytoreductive surgery	The three models were able to predict suboptimal cytoreductive, but they were more reliable for predicting complete cytoreductive surgery.	The R4 model discriminated better because it includes the laparotomic evaluation of the peritoneal carcinomatosis index.
44								
45								
46								
47								
48								
49								
50								
51								
52								
53								
54								
55								

1 Manuscript title: Laparoscopic prediction of primary cytoreducibility of epithelial ovarian cancer

2
3
4 Running title: Laparoscopic score of cytoreducibility in ovarian cancer

5
6
7
8
9 Tullio GOLIA D'AUGE' ^{1*}, Ilaria CUCCU ¹, Emanuele DE ANGELIS ¹, Violante DI DONATO
10 ¹, Ludovico MUZZI ¹, Ottavia D'ORIA ^{2,3}, Vito CHIANTERA ^{4,5}, Sandro GERLI ⁶, Donatella
11 CASERTA ⁷, Aris Raad BESHARAT ^{2,7}, Antonio Simone LAGANA' ^{4,8}, Giorgio BOGANI ⁹,
12 Alessandro FAVILLI ⁶, Andrea GIANNINI ^{1,2}

13
14
15
16 ¹ Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy;
17 tullio.goliadauge@uniroma1.it; andrea.giannini@uniroma1.it; ilaria.cuccu@uniroma1.it; emanuele.deangelis@uniroma1.it;
18 violante.didonato@uniroma1.it; ludovico.muzzi@uniroma1.it.

19
20 ² Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in
21 "Translational Medicine and Oncology", Sapienza University, 00189 Rome, Italy;
22 besharataris@gmail.com.

23
24 ³ Obstetrics and Gynecological Unit, Department of Woman's and Child's Health, San
25 Camillo-Forlanini Hospital, 00152 Rome, Italy; ottavia.doria@uniroma1.it.

26
27 ⁴ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical
28 Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy; vito.chiantera@unipa.it
29 (V.C.); antoniosimone.lagana@unipa.it

30
31 ⁵ Unit of Gynecologic Oncology, National Cancer Institute - IRCCS - Fondazione "G.
32 Pascale", 80131 Naples, Italy.

33
34 ⁶ Unit of Obstetrics and Gynecology, Department of Medicine and Surgery, University of
35 Perugia, 06123 Perugia, Italy; sandro.gerli@unipg.it; alessandro.favilli@unipg.it.

36
37 ⁷ Gynecology Division, Department of Medical and Surgical Sciences and Translational
38 Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, 00189 Rome, Italy;
39 donatella.caserta@uniroma1.it.

40
41 ⁸ Unit of Obstetrics and Gynecology, "Paolo Giaccone" Hospital, 90127 Palermo, Italy.

42
43 ⁹ Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di
44 Milano, Milano, Italy; boganigiorgio@gmail.com.

45
46 * Corresponding author: T. Golia D'Augè, Department of Maternal and Child Health and
47 Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy,
48 tullio.goliadauge@uniroma1.it
49
50
51
52
53
54
55

1 Abstract: Ovarian cancer affects thousands of women every year and represents the female cancer
2 with the highest mortality rate. Effectively, it is a severe disease that requires a multidisciplinary
3 approach for optimal treatment. Surgery currently is the cornerstone of its treatment and
4 numerous methods have been analyzed and developed to predict the possibility of obtaining a
5 residual tumor of 0 (RT=0). This review aims to analyze the available data in the literature
6 about minimally invasive surgical methods to predict an RT=0 in patients with advanced
7 epithelial ovarian carcinoma undergoing primary debulking surgery. An accurate review of the
8 literature has been performed on the available data about the surgical criteria of cytoreducibility
9 during primary debulking surgery. An accurate assessment of the extent of intra- and extra-
10 abdominal pathology is essential to guide the surgeon in the most appropriate therapeutic choice for
11 patients with ovarian cancer and multidisciplinary approaches that combine different
12 methodologies such as radiological methods (magnetic resonance imaging, positron emission
13 tomography and computed tomography), surgical (mini-laparotomy, laparoscopy) and serological
14 (CA-125, HE4) data provide a complete picture in determining the extent of the tumor and an
15 enormous aid in personalizing the therapeutic approach.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
Keywords: ovarian cancer; gynecologic oncology; gynecologic surgery; debulking surgery; PDS;
laparoscopy.

TEXT

1. Introduction

The most frequent ovarian malignancies are epithelial tumors. Ovarian cancer affects thousands of women every year and represents the female cancer with the highest mortality rate, with an estimated 13,270 deaths in the US in 2023¹⁻³. It is most common in women over the age of 50 and its lethality is due to delayed diagnosis until advanced stages (International Federation of Gynecology and Obstetrics – FIGO stage III-IV) and to the actual lack of screening programs for an early diagnosis, compared with other gynecological tumors (in particular, breast and cervical cancer)⁴⁻⁹; moreover, epithelial ovarian carcinomas clinically manifest with poor and non-specific signs and symptoms until most advanced stages^{10,11}. The centralization of ovarian cancer care in specialized centers has been demonstrated to improve outcomes thanks to the presence of a multidisciplinary team with specialized expertise, the possibility to access clinical trials and a streamlined approach to care, facilitating efficient and coordinated treatment plans; however, recently, the survival of patients with advanced epithelial ovarian cancer (AEOC) has radically increased and their prognosis has greatly improved^{12,13}; on the one hand, the possibility of subjecting patients with increased genetic risk of developing ovarian cancer (especially with mutations of the breast cancer gene (BRCA) and homologous recombination deficiency (HRD)) to a structured screening allows a more early diagnosis; on the other hand, the introduction of antiangiogenic and poly-ADP ribose polymerase (PARP) inhibitors (PARPi) opened up new therapeutic scenarios¹⁴⁻²⁴.

Currently, surgery followed by systemic therapy is the cornerstone of the treatment of AEOC²⁵⁻³¹; however, it is essential to personalize the therapeutic approach considering patients and tumor characteristics. The goal of the surgical treatment is to reduce the residual tumor load to 0 (RT=0), meaning the absence of macroscopically visible pathology. For this purpose, the surgical approach to AEOC provides two possibilities: primary surgical treatment (primary debulking surgery, PDS) or, interval debulking surgery (IDS), performing surgery after 3 or more cycles of platinum-based chemotherapy to reduce the burden of disease. Patients may not be eligible for upfront surgery for a high load of disease and/or for the involvement of anatomical structures that cannot be excised with surgery, for the massive involvement of organs, for example, the small and the large intestine, which would require the total or almost total removal with a consequent complete loss of function, for patient's fragility, that increases the risk of intra, peri- and post-operative complications and cause an additional risk of death³²⁻⁴¹. Assessing the extent of advanced ovarian cancer requires a multidisciplinary approach involving oncologists, gynecological surgeons, radiologists and other specialists. Several methods have been analyzed and developed to predict the possibility of obtaining RT=0 (genetic, imaging, serological, surgical), but, to date, none of them can be considered the gold standard. Despite the known advantages of

1 laparoscopic surgery in minimizing patient morbidity, in cases of uncertain operative status, an
2 exploratory laparotomy may be strategically considered. This procedure essentially consists of a
3 surgical dissection of the abdomen that allows a direct tissue assessment. This on-site examination
4 facilitates the accurate determination of the extent of neoplastic pathology and the subsequent
5 feasibility of cytoreduction surgery.
6

7
8 The main objective of the treatment of AEOC is to balance the risks to which the patient is exposed
9 to achieve RT=0, the surgical effort and the achievement of an optimal cytoreduction. This is
10 a narrative review aims to analyze the data available in the literature about minimally invasive surgical
11 methods to predict the optimal cytoreduction of patients with AEOC undergoing PDS.
12
13
14

15 2. Materials and Methods

16
17 This is a narrative review of the available data about the criteria of cytoreducibility during PDS for
18 the surgical treatment of AEOC. The review was reported and qualitatively assessed following the
19 SANRA, the Scale for the Assessment of Narrative Review Articles⁴². We performed the research
20 using a narrative review method⁴³. Electronic databases PubMed (MEDLINE), Embase, Scopus,
21 and Web of Science were searched until May 2023 (without date restriction) for relevant
22 publications in the English language focusing on the use of the following key search terms:
23 ovarian cancer OR advanced epithelial ovarian cancer OR ovarian serous carcinoma AND
24 cytoreduction OR cytoreducibility AND laparoscopic OR mini-invasive technique OR mini-
25 invasive surgery AND primary debulking surgery OR PDS OR upfront surgery. The electronic
26 search and the eligibility of studies were independently assessed by two authors (T.G.D and I.C.).
27 No restrictions on the study design were applied. The first selection was based on the title, the second
28 on the abstract, and the third on the full-text article. The bibliography was also analyzed to avoid
29 missing potentially relevant publications. The most relevant articles for this narrative review were
30 included.
31
32
33
34
35
36
37
38
39
40

41 3. Results

42
43 The role of laparoscopy in mapping advanced ovarian disease dissemination is widely recognized.
44 This is evident in authoritative sources such as the recent ESMO-ESGO consensus conference
45⁴ and in the American guidelines issued by the National Comprehensive Cancer Network®
46 (NCCN®)⁴⁴, where laparoscopy is accepted as a reliable prediction tool for quantifying tumor
47 burden and it is an optimal predictor for cytoreduction planning.
48
49

50 The studies included are summarized in Table 1.

51
52 The first study to determine the role of diagnostic laparoscopy in detecting optimally cytoreducible
53 patients (reported in the study as $RT \leq 1$ cm) was performed by an Italian group in 2005⁴⁵. A total
54
55

1 of 64 patients underwent a diagnostic LPS, in 60.9% of cases, the abdominal disease during
2 laparoscopy was judged to be suitable to reach $RT \leq 1$ cm. In the remaining 39.1% a mini
3 laparotomy was performed to re-evaluate the extent of the disease and the concordance rate about
4 an impossible optimal cytoreduction was 100%.
5

6 The use of scoring systems represents a method for comparing results and attributing them
7 objectively to determine the most appropriate treatment for each patient and to minimize
8 unnecessary laparotomies.
9

10 Interestingly, the pathological involvement of some anatomical structures allows predicting with
11 good accuracy (at least 80%) the possibility of performing an optimal cytoreduction: ovarian masses,
12 omental cake, peritoneal carcinosis, diaphragmatic carcinosis, mesenteric retraction, bowel
13 infiltration, stomach infiltration, liver metastases and bulky lymph nodes.
14

15 These parameters were re-analyzed by the same group in a subsequent study⁴⁶. A score including 6
16 of the listed anatomical districts has been proposed to classify patients into optimally and not
17 optimally cytoreducible. The presence of ovarian masses and macroscopically pathological lymph
18 nodes did not meet the authors' inclusion criteria for inclusion in the proposed score (specificity \geq
19 75%, positive predictive value (PPV) \geq 50%, and negative predictive value (NPV) \geq 50%). Each
20 parameter included in the score was assigned a value of 2 and a score was assigned to each patient.
21 This score has been defined as "predictive index score" (PIV, also known as "Fagotti score") and
22 the cut-off ≥ 8 identified patients undergoing suboptimal surgery. Subsequently, an attempt to
23 validate this score externally was made comparing the values assigned to each variable and the
24 overall PIV obtained in 17 centers specialized in gynecological oncological surgery with those of
25 the center where the score was created⁴⁷. An accuracy of more than 80% has been achieved in all
26 centers except one.
27

28 A modified score was proposed in 2008 by Brun et al. including, only 4 of the 8 anatomical structures
29 identified by Fagotti et al.: diaphragmatic carcinosis, mesenteric retraction, stomach infiltration and
30 liver metastases⁴⁸. Each of the listed parameters is assigned a value of 2 if macroscopically involved
31 by the disease and a cut-off ≤ 4 was identified to consider the patient optimally cytoreducible. The
32 authors concluded that the use of this modified score allowed the detection of patients not optimally
33 cytoreducible with sensitivity, specificity, PPV, NPV, and accuracy of 35%, 100%, 100%, 43%, and
34 56% respectively.
35

36 Petrillo et al., identifying 2 variables as "absolute criteria of unresectability" (miliaric carcinomatosis
37 on the serosa of the small bowel and mesenterial retraction), proposed an alternative modified score
38 evaluating 6 variables: (1) massive peritoneal involvement and/or a miliary pattern of distribution
39 for parietal peritoneal carcinomatosis; (2) widespread infiltrating carcinomatosis, and/or confluent
40 nodules to the most of the diaphragmatic surface; (3) tumor diffusion along the omentum up to the
41 large stomach curvature; (4) possible large/small bowel resection (excluding, recto-sigmoid
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1 involvement, giving its pelvic localization and since posterior exenteration is considered a standard
2 surgical procedure in AEOC); (5) obvious neoplastic involvement of the stomach, and/or lesser
3 omentum, and/or spleen; and (6) liver surface lesions larger than 2 cm ⁴⁹. After retrospectively
4 applying this score to 234 patients they demonstrated that a PIV >10 correlated with the
5 impossibility of obtaining an optimal cytoreduction (RT < 1 cm) with a positive predictive value of
6 100%; moreover, this PIV value was associated with a high (85.7%) rate of postoperative
7 complications (Clavien/Dindo 5-6).

8
9
10
11
12 Another Italian group in 2006 demonstrated that the use of laparoscopy allowed to selection of
13 patients eligible for optimal cytoreduction based on the intrabdominal extension of disease ⁵⁰.
14 Eighty-seven patients have undergone a diagnostic laparoscopy and 37 of them received neoadjuvant
15 chemotherapy because they were not considered able to tolerate major surgery (4/87 patients; 4.6%)
16 or due to the detection of at least one of the following (30/34; 88,2%): extended visceral peritoneal
17 metastases, large involvement of upper abdomen, extended small bowel involvement, multiple liver
18 metastases, heavily bleeding tumoral tissue. Due to the use of a minimally invasive technique, the
19 authors found a low rate of major complications in both groups (only 1 case in the group of patients
20 considered fragile or with advanced disease), with RT=0 in the PDS group of 96% and in the IDS
21 group of 86%, finding only 2 metastases localized at the 5 mm trocar's access. Moreover, the authors
22 compared the data obtained with those obtained before the introduction of laparoscopy as a
23 technique to guide the therapeutic path of patients with ovarian cancer; indeed, although debulking
24 surgery was performed only in 61% of cases (obtaining any residual disease), much lower than 95%
25 in the previous period, the optimal debulking rate was increased from 46% to 96%.

26
27
28
29
30
31
32 The first multicentric randomized controlled trial (RCT) on this topic was published in 2017 by
33 Rutten et al. ⁵¹ including 201 patients with epithelial ovarian cancer (EOC). Thanks to the use of a
34 minimally invasive technique the rate of not optimal cytoreduction (RT > 1 cm) was significantly
35 reduced compared to the counterpart (10% vs 39%, relative risk [RR], 0.25; 95% CI, 0.13 to 0.47;
36 p=0.001). The parameters used to predict the non-cytoreducibility during laparoscopy were
37 principally the extensive involvement of the diaphragmatic peritoneum and the presence of diffuse
38 intrabdominal disease. No significant differences were found in overall survival (OS) and
39 progression-free survival (PFS) between the groups analyzed.

40
41
42
43
44 Although Fagotti's index is mostly used by gynecological oncology specialists in Europe for
45 predicting surgical cytoreduction, laparoscopic predictive models used for ovarian cancer analysis
46 also include the peritoneal carcinosis index, originally described by Sugarbaker ⁵². The abdominal
47 cavity is divided into nine anatomical regions, right and left hypochondrium, epigastrium, right and
48 left flank, mesogastrium, right and left iliac fossa and hypogastrium. In addition, four specific
49 subdivisions corresponding to the gastrointestinal tract are delineated: the upper jejunum, the lower
50 jejunum, the upper ileum and the lower ileum. Each area is evaluated according to a scoring system
51
52
53
54
55

1 in which it is assigned: 0 with no evidence of tumor; 1 when the tumor is less than 0.5 cm; 2 when
2 the tumor is between 0.5 and 5 cm; 3 when the tumor exceeds 5 cm or merges with other lesions.

3 The total score varies between 0 and 39, with a 'cut-off' value between 10 and 20 to determine the
4 adequacy of surgical cytoreduction^{53,54}.

5
6 Recently, Di Donna et al. suggested that the laparoscopic score assessment had high accuracy for
7 optimal cytoreduction in AOEC patients undergoing PDS or IDS⁵⁵: in particular, in patients
8 undergoing PDS, the laparoscopic Predictive Index (PI) and the laparotomic Peritoneal Cancer Index
9 (PCI) had the best accuracies for complete cytoreduction (R0); in women undergoing IDS, the
10 laparotomic PI (Area under the ROC Curve (AUC) = 0.75) and the laparoscopic PCI (AUC= 0.87)
11 were associated with the best accuracy in RT=0 prediction.

12
13 A comparative analysis of the scores developed by Sugarbaker and Fagotti, aimed at assessing their
14 efficacy in predicting complete debulking, performed by either laparoscopic or laparotomic
15 approaches, was conducted within a non-randomized retrospective study conducted by Climent et
16 al⁵⁶. This study involved a cohort of 34 patients who met the eligibility criteria, 85.3% of whom had
17 peritoneal carcinomatosis of ovarian origin. The analysis revealed that the peritoneal carcinomatosis
18 indicator proved to be the strongest predictor, regardless of the surgical approach employed
19 (laparoscopic or laparotomic).

20
21 The results of the analysis indicated that when the Peritoneal Carcinomatosis Score (PCI) \geq 20, the
22 test achieved a sensitivity and specificity of 43% and 88%, respectively. The overall accuracy of the
23 index was 79%, with positive and negative prediction values of 50% and 86%, respectively.

24
25 The R3 and R4 models are alternative predictive models to assess suitability for surgical
26 cytoreduction for advanced ovarian cancer⁵³. Overall, 110 patients with advanced ovarian cancer
27 were included. The data extracted from the cohort were used to develop two separate predictive
28 models. Clinical, pathological and surgical data were collected and submitted for analysis to
29 determine the Peritoneal Tumor Load Index (PCI) and the Lesion Size Relative Score. The R3 model
30 score is a measure of the severity of the bowel obstruction, based on preoperative imaging, surgical
31 findings, and clinical symptoms. The R4 model score adds operative PCI to the R3 model score,
32 which may provide a more accurate assessment of the severity of the obstruction and the risk of
33 complications. Lesions were evaluated in 13 different anatomical regions within the abdomen and
34 pelvis, with subsequent transposition of the respective dimensions into a numerical scale ranging
35 from 0 to 3, contributing to an overall maximum score of 39. If more than one lesion was found
36 within a single region, the largest was included in the score calculation. Complete cytoreduction was
37 categorized as the macroscopic absence of tumor residual; optimal cytoreduction was defined as the
38 presence of a residual tumor with a diameter of less than 1 centimeter; suboptimal cytoreduction
39 was established in the presence of a residual tumor greater than 1 centimeter. Each model presented
40 a tripartite stratification of risk score and proved capable of predicting both suboptimal or complete
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1 and optimal surgical cytoreduction eligibility, with a sensitivity of 83% (R4 model) and 69% (R3
2 model), respectively. A PCI > 20 was found to be a significant risk factor for surgical unresectability.
3 A subsequent study conducted by Lluëca A et al.⁵⁷ analyzed the prognostic performance of these
4 models, comparing them with the Fagotti model, to predict suboptimal surgical cytoreduction in a
5 cohort of 103 patients with advanced ovarian cancer. The results showed that the three models were
6 able to satisfactorily predict suboptimal surgical cytoreduction for advanced ovarian cancer,
7 although they were most reliable in predicting complete surgical cytoreduction. Model R4
8 demonstrated superior efficacy compared to the others by the inclusion of laparoscopic assessment
9 of the peritoneal carcinomatosis index.

16 4. Discussion

17 After the introduction into clinical practice of maintenance therapies (in particular Vascular
18 endothelial growth factor (VEGF) inhibitors and PARPi(s)), ovarian epithelial carcinomas can be
19 considered a chronic disease^{4,17,19-21,58}. Therefore, although relapse rates change according to the
20 type of maintenance therapy that each patient can benefit from, according to the molecular status
21 (mutations in BRCA and HRD genes) and the County's reimbursement policy, the course of the
22 disease is predominantly influenced by the radicality of the surgical treatment (primary or after
23 neoadjuvant chemotherapy)^{19-23,59}.

24 At present, obtaining an absent residue of disease is the main goal of the surgical approach; indeed,
25 an RT=0 is a breakpoint to direct each patient toward a first-instance surgery or its reevaluation after
26 3 or more cycles of platinum-based chemotherapy⁶⁰⁻⁶³.

27 The ability to perform optimal cytoreduction is a crucial aspect of cancer surgery. It is primarily tied
28 to the extent of the disease and its accurate assessment is essential. However, it should be noted that
29 the main challenge in this context is the validation of predictive models. For this reason, several
30 authors have proposed surgical and non-surgical models aimed at assessing the feasibility and
31 success of optimal cytoreduction of advanced ovarian cancer^{52,53,64}.

32 The complexity of laparoscopy in advanced ovarian carcinoma is intrinsically related to its limited
33 ability to exhaustively explore deep abdominal cavities. This inherent restriction results in a
34 limitation in anatomical imaging, which may be a major determinant of tumor surgical
35 unresectability. Specifically, anatomical regions such as the hepatic pedicle, the retrohepatic region
36 and the retroperitoneal space may be under-represented or even completely inaccessible by the
37 laparoscopic approach and there is a need for advanced and specific imaging methodologies to
38 conduct an accurate analysis of these anatomical regions. This approach is a crucial tool to minimize
39 the adoption of unnecessary laparotomies⁶⁵.

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1 Several authors have reported promising results in predicting the suitability for optimal
2 cytoreduction using radiological imaging alone; however, it is imperative to emphasize that these
3 results have not yet been universally validated ⁶⁶.
4

5 Axtell et al. analyzing the data of 65 patients with AEOC subjected to PDS have identified 2
6 predictors of suboptimal cytotoxicity evaluable with CT scan: the presence of diaphragmatic disease
7 and the involvement of the intestinal mesentery (risk ratio 5.69 e 6.07, respectively) ⁶⁷. However,
8 the authors suggest using such predictors critically in the decision between upfront surgery and IDS.
9 Other authors have hypothesized a role of the massive ascitic effusion in predicting an optimal
10 cytoreduction, however, without demonstrating any statistically significant correlation ^{62,68,69}.
11

12 In this same line of research, Gerestein et al. conducted a study including of 115 patients to develop
13 a nomogram based on predictive parameters that may facilitate the prediction of suboptimal
14 cytoreduction ⁷⁰. The analysis identified that preoperative platelet count (p=0.1990), diffuse
15 peritoneal thickening (p=0.0074), and the presence of ascites in at least two-thirds of the CT scan
16 sections were predictive of residual disease greater than 1 centimeter after cytoreduction. This
17 nomogram accurately predicted the surgical outcome in 74% cases. However, further external
18 validation studies are needed to confirm the reliability and applicability of this tool in clinical
19 practice.
20

21 Moreover, gene expression analysis emerges as a constantly developing field of research. This
22 discipline focuses on understanding and utilizing genetic information to prescribe the most
23 appropriate therapeutic strategy for patients with malignancies. This approach assumes that the
24 genetic profile of tumors may condition the response to specific treatments and assumes a key role
25 in determining whether surgical action is warranted, as well as outlining the appropriate timing and
26 extent of surgery. This is achieved through the application of sophisticated methodologies for
27 analyzing the genetic profile of tumors, such as transcriptomic analysis of messenger RNA and
28 genomic investigation of genetic mutations. In a study conducted by Reem Abdallah et al. an initial
29 analysis was carried out involving over 12,000 genes. This investigation revealed that 58 of these
30 genes had a predictive accuracy for cytoreduction of 69% (p = 0.005). In a second in-depth analysis,
31 220 genes emerged as predictors of cytoreduction accuracy in 74% of cases. Unfortunately, these
32 patterns were not uniformly confirmed in independently conducted gene expression experiments ⁷¹.
33 Furthermore, several tumor markers have been proposed to predict the cytoreductivity of malignant
34 ovarian tumors: Angioli et al. proposed a value of the serum tumor marker Human epididymis
35 protein 4 (HE4) ≤ 262 pmol/L as predictive of RT ≤ 1 cm; studies on the use of pre-operative cancer
36 antigen 125 (CA125) values are conflicting about the possibility of its use as a predictor of surgical
37 radicality ⁷². The association of different parameters has been considered to propose an accurate
38 score without having reached this goal until now ⁷³⁻⁷⁵. Interestingly, further therapeutic targets are
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1 under evaluation⁷⁶⁻⁸⁰. Prediction of optimal cytoreduction through gene and marker expression is an
2 evolving field that could have a significant impact on personalizing treatments for cancer patients.
3 Many radiomic nomograms based on MRI image analysis were developed, demonstrating a
4 remarkable accuracy, sensitivity, and specificity of 85.0%, 87.0%, and 80.0%, respectively,
5 suggesting that MRI-based radiomic nomograms may be a reliable tool to guide therapeutic
6 decisions and improve the accuracy in predicting therapeutic outcomes in patients with advanced
7 ovarian cancer^{81,82}.

8 Finally, the Cukurova score was recently proposed for stratifying patients who may benefit from
9 primary debulking surgery⁸³. This score integrates the performance status of each patient with
10 laparoscopic and video-assisted thoracic surgery parameters, clinical parameters and anticipated
11 surgical procedures with imaging. The authors showed that a cut-off ≤ 12 can predict in over 96%
12 of cases a complete cytoreduction rate at primary debulking surgery for AEOC, moreover, a score
13 >12 correlated with post-operative complication rates and higher mortality⁸³.

14 In conclusion, the assessment of the extent of intra- and extra-abdominal pathology is of paramount
15 importance in the management of patients with AEOC. By using a multidisciplinary approach that
16 combines radiological methods such as MRI, PET and computed tomography, surgical techniques
17 such as mini-laparotomy and laparoscopy, and genetic and serological markers such as CA-125 and
18 HE4, it is possible to customize the therapeutic approach for these patients. The use of advanced
19 imaging methods such as MRI and PET allows for a more detailed assessment of the extent of the
20 disease, identifying possible metastases and involvement of surrounding tissues. Mini-LPTM and
21 LPS surgical techniques offer less invasive options for the removal of ovarian tumors while reducing
22 recovery time and potential side effects. Genetic markers such as CA-125 and HE4 can provide
23 further information on the presence and severity of the tumor. In addition, these markers can be used
24 to monitor response to treatment and disease recurrence. The multidisciplinary approach described
25 is essential to improve the outcomes of patients with AEOC, allowing the most appropriate treatment
26 to be adopted according to the severity and extent of the disease. This holistic approach aims to
27 improve the quality of care and provide personalized treatment to people facing the challenges of
28 advanced epithelial ovarian cancer.
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 REFERENCES

- 44 1. Cancer of the Ovary - Cancer Stat Facts Available online:
45 <https://seer.cancer.gov/statfacts/html/ovary.html> (accessed on 23 October 2023).
 - 46 2. Ovarian Cancer Statistics | How Common Is Ovarian Cancer Available online:
47 <https://www.cancer.org/cancer/types/ovarian-cancer/about/key-statistics.html> (accessed on 23
48 October 2023).
- 49
50
51
52
53
54
55

- 1 3. Pecorino B, Laganà, A.S, Chiantera V, Ferrara M, Di Stefano A.B, Di Donna M.C, et al.
2 Progression Free Survival, Overall Survival, and Relapse Rate in Endometrioid Ovarian Cancer and
3 Synchronous Endometrial-Ovarian Endometrioid Cancer (SEO-EC): Results from a Large
4 Retrospective Analysis. *Medicina (Kaunas)* 2022, 58, 1706
5
6
- 7 4. Colombo N, Sessa C, Du Bois A, Ledermann J, McCluggage W.G., McNeish I, et al.
8 ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and
9 Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease†. *Ann
10 Oncol* 2019, 30, 672–705
11
12
- 13 5. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann, J, et al.
14 ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and
15 Follow-Up. *Ann Oncol* 2016, 27, 16–41
16
17
- 18 6. Giannini A, Di Donato V, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, et al.
19 Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after
20 Cervical Conization. *Vaccines (Basel)* 2023, 11, 698
21
22
- 23 7. Coleman C. Early Detection and Screening for Breast Cancer. *Semin Oncol Nurs* 2017, 33,
24 141–155
25
26
- 27 8. Bevers T.B, Helvie M, Bonaccio E, Calhoun K.E, Daly M.B, Farrar W.B, et al. Breast
28 Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.
29 *J Natl Compr Canc Netw* 2018, 16, 1362–1389
30
31
- 32 9. Giannini A, Bogani G, Vizza E, Chiantera V, Laganà A.S, Muzii L, et al. Advances on
33 Prevention and Screening of Gynecologic Tumors: Are We Stepping Forward? *Healthcare (Basel)*
34 2022, 10, 1605
35
36
- 37 10. Raspagliesi F, Bogani G, Benedetti S, Grassi S, Ferla S, Buratti S. Detection of Ovarian
38 Cancer through Exhaled Breath by Electronic Nose: A Prospective Study. *Cancers (Basel)*.
39 2020;12(9):2408.
40
41
- 42 11. Fischetti M, Di Donato V, Palaia I, Perniola G, Tomao F, Perrone C, et al. Advances in
43 Small Molecule Maintenance Therapies for High-Grade Serous Ovarian Cancer. *Expert Opin
44 Pharmacother* 2023, 24, 65–72
45
46
- 47 12. Bogani G, Ditto A, Pinelli C, Lopez S, Chiappa V, Raspagliesi F. Ten-year follow-up
48 study of long-term outcomes after conservative surgery for early-stage ovarian cancer. *Int J
49 Gynaecol Obstet*. 2020;150(2):169-176
50
51
52
53
54
55

- 1 13. Margioulas-Siarkou C, Petousis S, Papanikolaou A, Gullo G, Margioulas-Siarkou G, Laganà
2 A.S, et al. Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer - State of the Art. Prz
3 Menopausal 2022, 21, 272–275
- 4
5
6
7 14. Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian Cancer Prevention and Screening.
8 Obstet Gynecol 2018, 131, 909–927,
9
- 10
11 15. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso M.J, Gilbert F, et al. ESMO
12 Guidelines Committee Prevention and Screening in BRCA Mutation Carriers and Other
13 Breast/Ovarian Hereditary Cancer Syndromes: ESMO Clinical Practice Guidelines for Cancer
14 Prevention and Screening. Ann Oncol 2016, 27, v103–v110
- 15
16
17 16. LeVasseur N, Chia S. Cancer Screening and Prevention in BRCA Mutation Carriers: A
18 Missed Opportunity? Br J Cancer 2019, 121, 1–2
- 19
20
21 17. Musella A, Vertechy L, Romito A, Marchetti C, Giannini A, Sciuga V, et al. Bevacizumab
22 in Ovarian Cancer: State of the Art and Unanswered Questions. Chemotherapy 2017, 62, 111–120
- 23
24
25 18. Tomao F, Marchetti C, Romito A, Di Pinto A, Di Donato V, Capri O, et al. Overcoming
26 Platinum Resistance in Ovarian Cancer Treatment: From Clinical Practice to Emerging Chemical
27 Therapies. Expert Opin Pharmacother 2017, 18, 1443–1455,
28
29
- 30
31 19. Moore K, Colombo N, Scambia G, Kim B.-G, Oaknin A, Friedlander M, et al. Maintenance
32 Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018, 379,
33 2495–2505
34
35
- 36 20. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib
37 plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 2019, 381, 2416–
38 2428
39
40
- 41 21. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza M.R,
42 et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019,
43 381, 2391–2402
44
45
46
- 47 22. Monk B.J, Coleman R.L, Fujiwara K, Wilson M.K, Oza A.M, Oaknin A, et al. ATHENA
48 (GOG-3020/ENGOT-Ov45): A Randomized, Phase III Trial to Evaluate Rucaparib as Monotherapy
49 (ATHENA-MONO) and Rucaparib in Combination with Nivolumab (ATHENA-COMBO) as
50 Maintenance Treatment Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer. Int
51 J Gynecol Cancer 2021, 31, 1589–1594,
52
53
54
55

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
23. Casarin J, Bogani G, Multinu F, Mariani A, Abu-Rustum N.R, Ghezzi F, et al. Paradigm Shifts in Gynecologic Oncology. *Int J Gynecol Cancer* 2021, 31, 1617
 24. Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, et al. In-House Testing for Homologous Recombination Repair Deficiency (HRD) Testing in Ovarian Carcinoma: A Feasibility Study Comparing AmoyDx HRD Focus Panel with Myriad MyChoiceCDx Assay. *Pathologica* 2022, 114, 288–294
 25. Fagotti A, Ferrandina M.G, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized Trial of Primary Debulking Surgery versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPION-NCT01461850). *Int J Gynecol Cancer* 2020, 30, 1657–1664
 26. Kotsopoulos I.C, Graham R, Mould T. SCORPION Study: Is It Time to Call Primary Debulking Surgery Superior? *Int J Gynecol Cancer* 2021, 31, 310
 27. Vergote I, Amant F, Kristensen G, Ehlen T, Reed N.S, Casado A. Primary Surgery or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery in Advanced Ovarian Cancer. *Eur J Cancer* 2011, 47 Suppl 3, S88-92
 28. Benedetti Panici P, Giannini A, Fischetti M, Lecce F, Di Donato V. Lymphadenectomy in Ovarian Cancer: Is It Still Justified? *Curr Oncol Rep* 2020, 22, 22
 29. Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, et al. Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies. *Ann Surg Oncol* 2017, 24, 1688–1697
 30. Peiretti M, Zanagnolo V, Aletti G.D, Boccione L, Colombo N, Landoni F, et al. Role of Maximal Primary Cytoreductive Surgery in Patients with Advanced Epithelial Ovarian and Tubal Cancer: Surgical and Oncological Outcomes. Single Institution Experience. *Gynecol Oncol* 2010, 119, 259–264
 31. Giannini A, D’Oria O, Bogani G, Di Donato V, Vizza E, Chiantera V, et al. Hysterectomy: Let’s Step Up the Ladder of Evidence to Look Over the Horizon. *J Clin Med* 2022, 11, 6940
 32. Aletti G.D, Gostout B.S, Podratz K.C, Cliby W.A. Ovarian Cancer Surgical Resectability: Relative Impact of Disease, Patient Status, and Surgeon. *Gynecol Oncol* 2006, 100, 33–37
 33. Aletti G.D, Dowdy S.C, Podratz K.C, Cliby W.A. Analysis of Factors Impacting Operability in Stage IV Ovarian Cancer: Rationale Use of a Triage System. *Gynecol Oncol* 2007, 105, 84–89

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
34. Di Donato V, Di Pinto A, Giannini A, Caruso G, D'Oria O, Tomao F, et al. Modified Fragility Index and Surgical Complexity Score Are Able to Predict Postoperative Morbidity and Mortality after Cytoreductive Surgery for Advanced Ovarian Cancer. *Gynecol Oncol* 2021, 161, 4–10
 35. Thrall M.M, Goff B.A, Symons R.G, Flum D.R, Gray H.J. Thirty-Day Mortality after Primary Cytoreductive Surgery for Advanced Ovarian Cancer in the Elderly. *Obstet Gynecol* 2011, 118, 537–547
 36. Armstrong D.K, Alvarez R.D, Bakkum-Gamez J.N, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021, 19, 191–226
 37. Bogani G, Borghi C, Ditto A, Signorelli M, Martinelli F, Chiappa V, et al. Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging. *J Minim Invasive Gynecol* 2017, 24, 739–746
 38. Davidson B.A, Broadwater G, Crim A, Boccacio R, Bixel K, Backes F, et al. Surgical Complexity Score and Role of Laparoscopy in Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy. *Gynecol Oncol* 2019, 152, 554–559
 39. Di Donato V, Giannini A, D'Oria O, Schiavi M.C, Di Pinto A, Fischetti M, et al. Hepatobiliary Disease Resection in Patients with Advanced Epithelial Ovarian Cancer: Prognostic Role and Optimal Cytoreduction. *Ann Surg Oncol* 2021, 28, 222–230
 40. Di Donato V, D'Oria O, Giannini A, Bogani G, Fischetti M, Santangelo G, et al. Age-Adjusted Charlson Comorbidity Index Predicts Survival in Endometrial Cancer Patients. *Gynecol Obstet Invest* 2022, 87, 191–199
 41. D'Oria O, Golia D'Auge T, Baiocco E, Vincenzoni C, Mancini E, Bruno V, et al. The Role of Preoperative Frailty Assessment in Patients Affected by Gynecological Cancer: A Narrative Review. *Ital J Gynaecol Obstet* 2022, 34, 76
 42. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. *Res Integr Peer Rev.* 2019;4:5.
 43. Gregory A.T, Denniss A.R. An Introduction to Writing Narrative and Systematic Reviews - Tasks, Tips and Traps for Aspiring Authors. *Heart Lung Circ.* 2018;27(7):893-898.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
44. Uterine Neoplasms Version 1.2024. Available online: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. (accessed on 23 October 2023).
45. Fagotti A, Fanfani F, Ludovisi M, Lo Voi R, Bifulco G, Testa A.C, et al. Role of Laparoscopy to Assess the Chance of Optimal Cytoreductive Surgery in Advanced Ovarian Cancer: A Pilot Study. *Gynecol Oncol* 2005, 96, 729–735
46. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A Laparoscopy-Based Score to Predict Surgical Outcome in Patients with Advanced Ovarian Carcinoma: A Pilot Study. *Ann Surg Oncol* 2006, 13, 1156–1161
47. Fagotti A, Vizzielli G, De Iaco P, Surico D, Buda A, Mandato V.D, et al. A Multicentric Trial (Olympia-MITO 13) on the Accuracy of Laparoscopy to Assess Peritoneal Spread in Ovarian Cancer. *Am J Obstet Gynecol* 2013, 209, 462.e1-462.e11
48. Brun J.-L, Rouzier R, Uzan S, Daraï E. External Validation of a Laparoscopic-Based Score to Evaluate Resectability of Advanced Ovarian Cancers: Clues for a Simplified Score. *Gynecol Oncol* 2008, 110, 354–359
49. Petrillo M, Vizzielli G, Fanfani F, Gallotta V, Cosentino F, Chiantera V, et al. Definition of a Dynamic Laparoscopic Model for the Prediction of Incomplete Cytoreduction in Advanced Epithelial Ovarian Cancer: Proof of a Concept. *Gynecol Oncol* 2015, 139, 5–9
50. Angioli R, Palaia I, Zullo M.A, Muzii L, Mancini N, Calcagno M, et al. Diagnostic Open Laparoscopy in the Management of Advanced Ovarian Cancer. *Gynecol Oncol* 2006, 100, 455–461
51. Rutten M.J, Gaarenstroom K.N, Van Gorp T, van Meurs H.S, Arts H.J, Bossuyt P.M, et al. Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Advanced Ovarian Cancer Patients (LapOvCa-Trial): A Multicentre Randomized Controlled Study. *BMC Cancer* 2012, 12, 31
52. Jacquet P, Sugarbaker P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat Res.* 1996;82:359-74.
53. Lluca A, Serra A, Delgado K, Maiocchi K, Jativa R, Gomez L, et al. A radiologic-laparoscopic model to predict suboptimal (or complete and optimal) debulking surgery in advanced ovarian cancer: a pilot study. *Int J Womens Health.* 2019;11:333-342.
54. Lluca A, Escrig, J, MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery). Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. *Eur J Surg Oncol.* 2018;44(1):163-169.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
55. Di Donna M.C, Cucinella G, Zaccaria G, Lo Re G, Crapanzano A, Salerno S, et al. Concordance of Radiological, Laparoscopic and Laparotomic Scoring to Predict Complete Cytoreduction in Women with Advanced Ovarian Cancer. *Cancers (Basel)* 2023, 15, 500
56. Climent M. T, Serra A, Gilabert-Estellés J, Gilabert-Aguilar J, Llueca, A. Comparison of Peritoneal Carcinomatosis Scoring Methods in Predicting Resectability and Prognosis in Gynecologic Malignancies. *J Clin Med.* 2021;10(12):2553.
57. Llueca A, Climent M.T, Escrig J, Carrasco P, Serra A, MUAPOS working group (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery). Validation of three predictive models for suboptimal cytoreductive surgery in advanced ovarian cancer. *Sci Rep.* 2021;11(1):8111.
58. Burger R.A, Brady M.F, Bookman M.A, Fleming G.F, Monk B.J, Huang H, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. *N Engl J Med* 2011, 365, 2473–2483,
59. Feys T. BROADENED REIMBURSEMENT CRITERIA FOR THE PARP INHIBITOR OLAPARIB Available online: <https://www.bjmo.be/broadened-reimbursement-criteria-for-the-parp-inhibitor-olaparib-in-prostate-breast-and-pancreatic-cancers/> (accessed on 23 October 2023).
60. Chiofalo B, Bruni S, Certelli C, Sperduti I, Baiocco E, Vizza E. Primary Debulking Surgery vs. Interval Debulking Surgery for Advanced Ovarian Cancer: Review of the Literature and Meta-Analysis. *Minerva Med* 2019, 110, 330–340
61. Sørensen S.M, Høgdall C, Mosgaard B.J, Dalgaard M.I.R, Jensen M.P, Fuglsang K, et al. Residual Tumor and Primary Debulking Surgery vs Interval Debulking Surgery in Stage IV Epithelial Ovarian Cancer. *Acta Obstet Gynecol Scand* 2022, 101, 334–343
62. Ghirardi V, Moruzzi M.C, Bizzarri N, Vargiu V, D’Indinosante M, Garganese G, et al. Minimal Residual Disease at Primary Debulking Surgery versus Complete Tumor Resection at Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer: A Survival Analysis. *Gynecol Oncol* 2020, 157, 209–213
63. Bryant A, Hiu S, Kunonga P.T, Gajjar K, Craig D, Vale L, et al. Impact of Residual Disease as a Prognostic Factor for Survival in Women with Advanced Epithelial Ovarian Cancer after Primary Surgery. *Cochrane Database Syst Rev* 2022, 9, CD015048,
64. Suidan R.S, Ramirez P. T, Sarasohn D. M, Teitcher J. B, Iyer R. B, Zhou Q, et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to

1 predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. *Gynecol*
2 *Oncol.* 2017;145(1):27-31.

3
4
5 65. Deffieux X, Castaigne D, Pomel C. Role of laparoscopy to evaluate candidates for complete
6 cytoreduction in advanced stages of epithelial ovarian cancer. *Int J Gynecol Cancer.* 2006;16 Suppl
7 1:35-40.

8
9
10 66. Feng Z, Wen H, Jiang Z, Liu S, Ju X, Chen X, et al. A triage strategy in advanced ovarian
11 cancer management based on multiple predictive models for R0 resection: a prospective cohort
12 study. *J Gynecol Oncol.* 2018;29(5):e65.

13
14
15 67. Axtell A.E, Lee M.H, Bristow R.E, Dowdy S.C, Cliby W.A, Raman S, et al. Multi-
16 Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal
17 Primary Cytoreduction in Patients with Advanced Ovarian Cancer. *J Clin Oncol* 2007, 25, 384–389,
18

19
20
21 68. Vergote I, de Wever, I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam, P. Interval
22 Debulking Surgery: An Alternative for Primary Surgical Debulking? *Semin Surg Oncol* 2000, 19,
23 49–53
24

25
26
27 69. Barlow T.S, Przybylski M, Schilder J.M, Moore D.H, Look K.Y. The Utility of Presurgical
28 CA125 to Predict Optimal Tumor Cytoreduction of Epithelial Ovarian Cancer. *Int J Gynecol Cancer*
29 2006, 16, 496–500
30

31
32 70. Gerestein C. G, Eijkemans M. J, Bakker J, Elgersma O. E, van der Burg M. E, Kooi G, et
33 al. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
34 *Anticancer Res.* 2011;31(11):4043-9.
35

36
37
38 71. Abdallah R, Chon H. S, Bou Zgheib N, Marchion D. C, Wenham R. M, Lancaster J. M, et
39 al. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression
40 Data. *Int J Gynecol Cancer.* 2015;25(6):1000-9.
41

42
43 72. Angioli R, Plotti, F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the
44 Preoperative HE4 Level Predict Optimal Cytoreduction in Patients with Advanced Ovarian
45 Carcinoma? *Gynecol Oncol* 2013, 128, 579–583
46

47
48 73. El-Agwany A.S. Laparoscopy and Computed Tomography Imaging in Advanced Ovarian
49 Tumors: A Roadmap for Prediction of Optimal Cytoreductive Surgery. *Gynecol Minim Invasive*
50 *Ther* 2018, 7, 66–69
51
52
53
54
55

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
74. Abdalla Ahmed S, Abou-Taleb H, Ali N, M Badary D. Accuracy of Radiologic-Laparoscopic Peritoneal Carcinomatosis Categorization in the Prediction of Surgical Outcome. *Br J Radiol* 2019, 92, 20190163
75. De Jong D, Eijkemans M.J, Lie Fong S, Gerestein C.G, Kooi G.S, Baalbergen A, et al. Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma. *Oncology* 2007, 72, 293–301
76. Gilbert L, Oaknin, A, Matulonis U.A, Mantia-Smaldone G.M, Lim P.C, Castro C.M., et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. *Gynecol Oncol.* 2023;170:241-247.
77. Indini A, Nigro O, Lengyel C.G, Ghidini M, Petrillo A, Lopez S, et al. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. *Cancers (Basel)*, 2021;13(7):1663.
78. Bogani G, Lopez S, Mantiero M, Ducceschi M, Bosio S, Ruisi S, et al. Immunotherapy for platinum-resistant ovarian cancer. *Gynecol Oncol.* 2020;158(2):484-488.
79. Bogani G, Monk B.J, Coleman R.L, Vergote I, Oakin A, Ray-Coquard I, et al. Selinexor in patients with advanced and recurrent endometrial cancer. *Curr Probl Cancer.* 2023:100963. doi: 10.1016/j.currproblcancer.2023.100963.
80. Bogani G, Coleman R.L, Vergote I, Raspagliesi F, Lorusso D, Monk B.J. Tisotumab vedotin in recurrent or metastatic cervical cancer. *Curr Probl Cancer.* 2023;47(3):100952.
81. Mao M. M, Li H. M, Shi J, Qiu Q. S, Feng F. [Prediction of platinum-based chemotherapy sensitivity for epithelial ovarian cancer by multi-sequence MRI-based radiomic nomogram]. *Zhonghua Yi Xue Za Zhi.* 2022;102(3):201-208. Chinese.
82. Wang T, Wang H, Wang Y, Liu X, Ling L, Zhang G, et al. MR-based radiomics-clinical nomogram in epithelial ovarian tumor prognosis prediction: tumor body texture analysis across various acquisition protocols. *J Ovarian Res.* 2022;15(1):6.
83. Khatib G, Seyfettinoglu S, Kose S, Kucukgoz Gulec U, Avcı A, Güzel AB, et al. The Cukurova score in the prediction of primary cytoreduction in ovarian cancer. *Int J Gynecol Cancer.* 2023:ijgc-2023-004736.

51
52
53
54
55

Conflicts of interest

The authors declare no conflict of interest.

1
2
3 Funding

4 This research received no external funding.
5
6

7 Authors' contributions

8
9 Conceptualization and writing—review and editing, T.G.D.; methodology and software, I.C.; E.D.A.;
10 validation, V.D.D., L.M. and O.D.; formal analysis, V.C.; investigation, S.G.; resources, A.R.B.; data
11 curation, A.S.L.; writing—original draft preparation, A.F.; L.M.; visualization, G.B., supervision, A.G.
12 and D.C.; project administration, V.D.D. All authors have read and agreed to the published version of
13 the manuscript.
14
15

16
17 Table legend

18 Table 1. Summary of studies included.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

PEER REVIEW COPY
Minerva Ginecologica

Table 1. Summary of studies included.

Author	Year	Type	N pat	Score	Objective	Results	Conclusion
Fagotti [45]	2005	Prospective	64	Fagotti score	Optimal cytoreduction	Accuracy rate of laparoscopy was 90%.	Laparoscopy can be considered imposable to standard longitudinal laparotomy in identifying not optimally resectable
Fagotti [46]	2006	Prospective	64	Fagotti score	Optimal cytoreductive surgery	A predictive index score ≥ 8 identified patients undergoing suboptimal surgery with a specificity of 100%	The reliability of laparoscopy in assessing the chance of optimal cytoreduction can be improved by using a simple scoring system.
Fagotti [47]	2013	Prospective	120	Fagotti score	Optimal cytoreduction	All but 1 satellite center, reached an accuracy rate of 80% or greater for both single parameters and overall score	LPS allows an accurate and reliable assessment of intraperitoneal diffusion of disease
Jean-Luc Brun [48]	2008	Retrospective	55	Modified score of Fagotti score	Optimal cytoreductive surgery	A modified score of ≥ 4 was associated with suboptimal cytoreduction.	This simplified laparoscopy-based score was at least as accurate as the Fagotti score to predict resectability
M Petrillo [49]	2015	Prospective	234	Laparoscopy-based predictive index model	Incomplete cytoreduction	At a Laparoscopy-based predictive index model ≥ 10 the chance of achieving complete Primary debulking surgery was 0, and the risk of unnecessary laparotomy was 33.2%.	Staging laparoscopy is confirmed as an accurate tool in the prediction of complete Primary debulking surgery
Roberto Angioli [50]	2006	Prospective	87	Diagnostic open laparoscopy	Optimal primary cytoreductive surgery	Diagnostic laparoscopy allows to select patients for optimal primary cytoreductive surgery.	Diagnostic open laparoscopy could be considered a valid diagnostic tool in evaluating the extent of disease
Marianne J Rutten [51]	2012	Randomized	200	Additional diagnostic laparoscopy	Suboptimal cytoreductive surgery	Patients who have disease considered to be resectable to less than one	Laparoscopy before starting treatment for ovarian cancer can be an additional diagnostic tool to predict the outcome of primary debulking surgery

1						centimeter should undergo primary debulking surgery to improve prognosis.		
2								
3								
4								
5								
6								
7								
8								
9	Antoni Lluca [53]	2019	Prospective, analyzed retrospectively	110	R4 model (included operative PCI), R3 model	Suboptimal and optimal cytoreductive surgery and	Sensitivity of 83% (R4 model) Sensitivity of 69% (R3 model)	PCI>20 was a major risk factor for unresectability
10								
11								
12								
13								
14	Antoni Lluca [54]	2018	Retrospective	80	PCI score	evaluate the prognostic value of PCI	PCI was significantly associated with suboptimal surgery	PCI may provide important information for surgical planning
15								
16								
17								
18								
19	Mariano Catello Di Donna [55]	2023	Retrospective	100 (69 underwent PD S 31 underwent NA CT and IDS)	Predictive Index score Peritoneal Cancer Index score	Complete cytoreduction	In patients undergoing PDS, the laparoscopic PI and the laparotomic PCI had the best accuracies for complete cytoreduction (R0) In the IDS group, the laparotomic PI were associated with the best accuracy in R0 prediction	Laparoscopic score assessment had high accuracy for optimal cytoreduction in patients undergoing PDS or IDS.
20								
21								
22								
23								
24								
25								
26								
27								
28								
29								
30								
31								
32								
33								
34	María Teresa Climent [56]	2021	Retrospective	34	Fagotti's index Sugarbaker's peritoneal cancer index	Optimal and suboptimal surgery	The rate of complete cytoreductive surgery was 79.4% The highest sensitivity was obtained with a PCI > 20.	The best diagnostic method to classify patients with peritoneal cancer is the PCI
35								
36								
37								
38								
39								
40								
41								
42	Antoni Lluca [57]	2021	Prospective, analyzed retrospectively	103	Fagotti R3 models R4 models	Suboptimal cytoreductive surgery	The three models were able to predict suboptimal cytoreductive, but they were more reliable for predicting complete cytoreductive surgery.	The R4 model discriminated better because it includes the laparotomic evaluation of the peritoneal carcinomatosis index.
43								
44								
45								
46								
47								
48								
49								
50								
51								
52								